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ABSTRACT
Laminitis is a crippling and often life-threatening disease of the equine foot. Soft tissue
damage characteristic of this disease has been associated with increased MMP activity.
Therefore, it seems likely that MMPIs could be potential therapeutic agents for laminitis. Further
characterization of equine MMPs and evaluation of the effectiveness of MMPIs in the horse are
needed.
Equine MMP-9 was harvested from neutrophils, purified by affinity chromatography, and
evaluated using western blotting and gelatin zymography. The Biotrak MMP-9 Activity Assay
was evaluated for use with equine samples using equine neutrophil MMP-9 as a standard, and
was determined to have insufficient sensitivity for equine MMP-9. Therefore, zymography was
used for evaluating MMP activity in all studies.
The abilities of doxycycline, oxytetracycline, and flunixin meglumine to inhibit LPSinduced equine MMP-2 and MMP-9 activities in vitro were investigated using a digital laminar
explant model. The structural integrity of the explants was tested using an Instron biomechanical
testing device, and MMP activity in the explants medium was evaluated using zymography.
Doxycycline, oxytetracycline, and flunixin meglumine all successfully inhibited equine MMP-9
to varying degrees. However, only doxycycline and oxytetracycline increased the structural
integrity of the explants. Explant structural integrity was inversely correlated with MMP-2
concentrations in the medium.
Based on the in vitro results, a non-terminal in vivo model for investigating MMPIs in the
horse was validated. The administration of IV endotoxin to normal adult horses resulted in
significant increases in MMP-2 and MMP-9 activities, as assessed by zymography. This in vivo
model of MMP induction was used to determine the effects of doxycycline, oxytetracycline,
flunixin meglumine, and pentoxifylline on equine MMP inhibition. Pentoxifylline and
xii

oxytetracycline appeared to be potent MMP-9 and modest MMP-2 inhibitors in the horse.
Flunixin meglumine and doxycycline were potent inhibitors of equine MMP-2, but only weak
inhibitors of equine MMP-9. These findings warrant the evaluation of pentoxifylline and
oxytetracycline as MMPIs in the prevention/treatment of equine laminitis.
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CHAPTER 1. INTRODUCTION/REVIEW OF LITERATURE

1

1.1 Introduction
The extracellular matrix (ECM) plays a critical role in normal tissue structure and
function. It is constantly undergoing remodeling via the actions of proteases, in particular,
matrix metalloproteinases (MMPs). During normal physiological events, MMPs are highly
regulated and necessary for homeostasis. However, in pathologic states, their enzymatic actions
may go unchecked and lead to substantial tissue destruction. Extensive evidence exists for the
role of MMPs in the pathophysiology of both human and animal diseases. Thus, MMPs have
become targets for therapeutic intervention by the development of MMP inhibitors (MMPIs).
Liberation of endotoxin from the cell wall of Gram-negative bacteria often leads to
endotoxemia and the subsequent induction of a systemic inflammatory response. Multiple
inflammatory mediator cascades are initiated that ultimately result in tissue destruction and death
if left untreated. Some of the many mediators responsible for the pathological changes
associated with endotoxemia include MMPs. The experimental administration of endotoxin has
been used in many species to study alterations in various mediator activities, including MMPs.
Although endotoxemia has been experimentally induced in horses, MMP activity has not been
investigated.
Laminitis is a crippling and often life-threatening disease of the equine foot. The
pathophysiology of laminitis remains unclear; however, recent studies suggest that MMPs are
responsible for the soft tissue damage associated with this disease. Therefore, it seems likely
that MMPIs could be potential therapeutic agents for laminitis. The induction of laminitis for
research is costly, emotionally difficult for researchers, and causes pain and discomfort for the
horses. Endotoxemia may be an effective model of MMP induction in the horse which can be
used for evaluating MMPIs for use in the prevention/treatment of equine laminitis.

2

1.2 Matrix Metalloproteinases
The function of MMPs cannot be fully understood without first understanding the
structure and function of the ECM. The main structural unit of the ECM is collagen. Collagens
provide the scaffolding necessary for structural integrity of tissues. There are over 20 distinct
collagens. Collagens types I, II, III, V, and XI assemble into fibrils that provide tissues such as
bone, cartilage, tendon, and skin with tensile strength. The basement membrane (BM) of the
ECM is composed mostly of type IV collagen and laminin.1,2 The BM also contains other
proteins such as type V collagen, growth factors, proteases, proteoglycans, and glycoproteins.2
Type IV and V collagens are organized into non-fibrillar multilayer networks (as are types VIII
and X) that are resistant to nonspecific proteolytic degradation.1,2 Proteoglycans adhere to the
collagen framework and function to support cell adhesion and bind growth factors.
The ECM functions to maintain tissue structure and integrity, regulate cellular migration,
and serve as a reservoir for various cytokines and growth factors.3 Multiple stimuli induce
remodeling of the ECM during homeostasis, normal development, and pathologic conditions.
Remodeling involves both ECM degradation and synthesis. Proteolytic breakdown is
accomplished via numerous proteases, especially MMPs.1
Proteases can be divided into exopeptidases and endopeptidases, or proteinases.
Endopeptidases are hydrolytic enzymes that are grouped according to the catalytic group at their
active site. Metalloproteases contain over 200 mostly zinc-dependent enzymes, of which only 25
or more are MMPs. The metzincin superfamily of metalloproteases contains the matrixin family,
also known as MMPs.4
Matrix metalloproteinases are a family of over 25 zinc-dependent endopeptidases that
degrade ECM components. They were first discovered when enzymes from tadpole tails
undergoing metamorphosis hydrolyzed a native collagen matrix.5 All MMPs share general basic
3

characteristics. They are secreted (except for the membrane-type) or anchored to the cell surface
in the pro enzyme form as zymogens that require cleavage for activation.4 They require Ca2+ for
stability and function at neutral pH.6,7
Proteases must contain at least two conserved motifs, a pro and catalytic domain, to be
classified as MMPs.8 Their structure usually contains a signal sequence followed by the Nterminal pro-domain.7 The pro domain is approximately 80 amino acids long and contains a
cysteine residue. The active, or catalytic, domain is approximately 170 amino acids long and
contains three histidines which ligate a Zn2+ active site.9 The inactive pro-enzymes are held in
the latent form by a “cysteine switch” mechanism which consists of the interaction between the
thiol moiety of the pro-domain cysteine residue and the Zn2+ of the active site. This interaction
blocks access of the active site to substrate and must be disrupted for activity.7 At the Cterminal, there is a hemopexin-like domain which aids in substrate recognition.10 Some MMPs
also have specialized domains that further determine substrate specificity and allow recognition
and interaction with other proteins.10
Matrix metalloproteinases not only perform matrix catalysis, but also regulate cell-cell
and cell-matrix interactions and activate other proteins. They act on membrane proteins or
proteins within the extracellular space.8 Their expression, location, and substrate availability
determine the proteolytic activity of MMPs in physiologic and pathologic inflammatory
processes.11 They are present in tissues for homeostasis, but can be induced for repair or
remodeling and during disease states by activated cells.8 Matrix metalloproteinases help to
regulate physical barriers, modulate inflammatory mediators, and establish chemokine gradients
for movement of leukocytes in inflamed tissue. Specifically, they degrade endothelial cell
junctional proteins to allow leukocyte migration into areas of infection or inflammation. They
help promote re-epithelialization and restoration of epithelial barriers against bacteria and other
4

invading pathogens. They also promote or suppress inflammation by proteolytic activation and
de-activation of cytokines and chemokines.11
Matrix metalloproteinases are grouped according to their substrate specificity and
primary structure (Table 1.1).7 Collagenases degrade fibrillar forms of interstitial collagen and
include interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8), and collagenase-3
(MMP-13). Gelatinase A and B (MMP-2 and MMP-9) degrade denatured collagen.
Stromelysins 1, 2, and 3 (MMP-3, 10, and 11) act on non-collagen components of the ECM.10
The matrilysins (MMP-7 and MMP-26) are the smallest of MMPs. There are 7 membrane-type
MMPs (MMP-14, 15, 16, 17, 23, 24, 25) which degrade ECM components as well as activate
other MMPs.7,12
The gelatinases are the most widely studied group of MMPs. Matrix metalloproteinase-2
is a 72-kD protein in its pro-enzyme form known as Gelatinase A. It degrades gelatin (denatured
collagen), along with type-IV, V, VII, and X collagen, elastin, laminin, and fibronectin.13
Gelatinase A is constitutively expressed by many structural cell types including endothelial cells,
osteoblasts, and fibroblasts.12 Its activation is unique in that it requires binding to tissue inhibitor
of MMP-2 (TIMP-2). Once bound, this complex is then activated by MMP-14, a membrane type
MMP (MT-MMP).14 Gelatinase B, or MMP-9, is a 92-kD protein in its pro-enzyme form. It
also degrades gelatin, types IV and V collagen, elastin, fibronectin, and plasminogen.13 Unlike
MMP-2, MMP-9 expression is generally induced. It is synthesized by leukocytes, predominately
neutrophils, fibroblasts, and keratinocytes. Neutrophils store preformed MMP-9 in tertiary
granules for immediate release that does not require de novo synthesis.7
Regulation of MMP activity is tightly controlled on several levels to prevent rampant
tissue destruction, including mRNA/protein expression, pro-enzyme activation, and
inhibition/degradation. Transcriptional regulation occurs through the cyclic adenosine
5

Table 1.1 – MMP nomenclature organized by group.

MMP NOMENCLATURE
Group

Name

MMP Number

Collagenase

Interstitial Collagenase
Neutrophil Collagenase
Collagenase-3
Collagenase-4
Gelatinase A
Gelatinase B
Stromelysin-1
Stromelysin-2
Stromelysin-3
Matrilysin
Matrilysin-2
MT1-MMP
MT2-MMP
MT3-MMP
MT4-MMP
MT5-MMP
MT6-MMP
Metalloelastase
RASI-I
Enamelysin
CA-MMP
Epilysin

MMP-1
MMP-8
MMP-13
MMP-18
MMP-2
MMP-9
MMP-3
MMP-10
MMP-11
MMP-7
MMP-26
MMP-14
MMP-15
MMP-16
MMP-17
MMP-24
MMP-25
MMP-12
MMP-19
MMP-20
MMP-23
MMP-28

Gelatinase
Stromelysin

Matrilysin
Membrane-Type

Others

6

monophosphate/p38/mitogen activated protein kinase (cAMP/p38/MAPK) pathway, and can be
induced or inhibited by various cytokines and growth factors, such as interleukin-1 (IL-1), IL-2,
tumor necrosis factor-α (TNF-α), epidermal growth factor (EGF), and platelet-derived growth
factor (PDGF).3,6,12,15-22 Other inflammatory mediators such as nitric oxide (NO), endothelin-1
(ET-1), eicosanoids such as prostaglandin E2 (PGE2), and neuropeptides such as vasoactive
intestinal peptide (VIP) have also been shown to induce or inhibit synthesis of MMP-2 and
MMP-9.15,21,23-26 Matrix metalloproteinase gene expression can also be influenced by cell-cell
interactions.27
Pro-enzyme activation of MMPs can occur through direct proteolytic cleavage of the prodomain via proteases such as plasmin, trypsin, elastase, tissue kallikrein, cathepsin-G, chymase,
and other MMPs.10,28,29 Activation may also occur by exposure to organomercurials, oxidated
glutathione, and reactive oxygen species (ROS).6,30 Heavy metal ions, such as mercurial
compounds, can activate MMP zymogens by reduction of the pro-domain thiol.4 Oxidants can
activate MMPs through oxidation of the pro-domain thiol and subsequent release of the Zn2+
active site allowing autolytic cleavage.31 Hypochlorous acid (HOCl), a ROS by-product of
leukocyte myeloperoxidase, and peroxynitrite, a by-product of NO release, have been shown to
activate MMP-2 and MMP-9.4,32-36 Several MMPs have also been found to undergo allosteric
activation without pro-domain removal when in contact with the appropriate substrate.31
Regulation of MMP activity occurs post-activation by interaction with endogenous MMP
inhibitors and degradation of the enzyme by ROS. Endogenous inhibitors include the nonspecific protease inhibitor α2-macroglobulin, TIMPs, and reversion-inducing-cysteine-rich
protein with kazal motifs (RECK).31,37 Circulating α2-macroglobulins bind MMPs to prevent
substrate attachment. The complexes are then cleared from the circulation by macrophage
endocytosis.31 In normal tissues, MMP activity is highly regulated by the MMP/TIMP
7

balance.3,38 To date, four TIMPs have been discovered and characterized (TIMP-1 through
TIMP-4). TIMP-1, 2, and 4 are in a soluble form, whereas TIMP-3 is associated with the ECM.
They all bind non-covalently in a 1:1 ratio with high affinity to both pro and active MMP
catalytic sites resulting in either prevention or loss of activity.7,39 TIMP-1 binds specifically with
MMP-9 and TIMP-2 with MMP-2, as previously stated. In addition to inactivating MMPs,
TIMPs also affect cell growth by inducing apoptosis.10 RECK is a membrane anchored
glycoprotein that inhibits MMP-2, MMP-9, and MMP-14 (MT-MMP-1). It has been suggested
that RECK regulates MMP activity through direct inhibition of protease activity, regulation of
cellular release, and cell surface sequestration.39 Degradation can occur via the same ROS that
activate MMPs through modification of amino acids that are essential for catalytic activity.31
Several techniques are available for the detection of MMP-2 and MMP-9; however,
gelatin zymography is most often used. Zymography utilizes electrophoresis to separate proteins
in a polyacrylamide gel impregnated with gelatin.40 Any MMP-2 or MMP-9 present in a sample
will degrade the gel at the appropriate molecular weights. Staining of the gels with Coomassie
blue allows MMP activity to be visualized as a clear band in the blue gel (Figure 1.1).
Zymography is highly specific for MMP-2 and MMP-9 activities, because they are the only
MMPs known to degrade gelatin; however, it is only semi-quantitative. Relative values can be
established for MMP concentrations by digitally scanning zymography gels and measuring band
intensity and size using a computerized densitometry program. Both pro and active forms of the
enzymes can be detected using zymography. The samples are diluted and subjected to
electrophoresis in buffers containing sodium dodecyl sulfate (SDS), which removes any
inhibitors present and activates the enzymes. The SDS is rinsed away following electrophoresis,
allowing the enzymes to renature and degrade the gel. Other procedures available for evaluation

8

Figure 1.1 – An example of a zymogram. The clear areas indicate the presence of MMPs.

9

of MMPs include enzyme-linked immunosorbant assays (ELISAs), fluorogenic assays, activity
assays, immunohistochemistry, and mRNA expression analysis.41,42
Numerous studies have shown that MMPs are crucial for normal tissue development,
remodeling, and homeostasis. They are active in many processes such as ovulation, blastocyst
implantation, embryonic development, postpartum uterine involution, bone remodeling,
angiogenesis, and apoptosis.43-49 Several MMPs modulate the activities of growth factors,
cytokines, and other mediators. Both MMP-2 and MMP-9 activate TNF-α and IL-1β.11,50 In
turn, IL-β can also be degraded by the gelatinases.51 Big ET-1 is cleaved into the potent
vasoconstrictor ET-1by MMP-2, a process which can be blocked by TIMP-2.52 Vascular
endothelial growth factor (VEGF), transforming growth factor-β (TGF-β), and EGF are all
released and activated through the enzymatic actions of MMPs.53-55
While MMPs are crucial for normal biological processes, they are mainly diseaseassociated enzymes. Almost all forms of cancer are associated with increases in MMPs, because
they are necessary for tumor metastasis and angiogenesis.56,57 Various neurological conditions
result from unregulated MMP activity at the blood brain barrier, which allows pathogens and
inflammatory cells access to the central nervous system (CNS).58,59 Increased MMP activity is
also associated with osteoarthritis, asthma, cardiovascular disease, and numerous other
diseases.6,10,60-64
In horses, MMPs have been identified in association with several pathologic conditions.
Matrix metalloproteinase-9 is involved in equine respiratory disease, in particular in recurrent
airway obstruction (RAO).65 Several studies have shown increased MMP-9 concentrations in
bronchioalveolar lavage fluid (BALF) and tracheal epithelial lining fluid (TELF) of horses with
RAO, and that elevations in MMP-9 are correlated with neutrophil numbers.66-68 Increased
MMP-8 and MMP-13 activities are also present in association with RAO, and can be inhibited
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by synthetic MMPIs.69,70 Increases in equine synovial fluid MMP-1, 2, 3, 9, and 13
concentrations are associated with osteoarthritis.71-76 Matrix metalloproteinase-13 mRNA
expression is up-regulated in equine superficial digital flexor tendonitis lesions, and MMP-9 is
suggested to be important in this disease as well.77,78 Increases in gelatinase activity have been
associated with colic, corneal ulceration, and endometriosis in horses.79-81 Studies have shown
increased MMP-2 and MMP-9 concentrations in laminar tissues of both experimentally-induced
and naturally-acquired equine laminitis.82-84 Increased mRNA expression of MMP-2 and MMP14 has also been found in laminar tissues of laminitic horses.85,86
As the role of MMPs in various pathological conditions has become more apparent,
attention has been focused on MMPIs as therapeutic agents. Synthetic MMPIs, such as
batimastat, marimastat, and others have been developed as potential treatments for diseases such
as cancer and arthritis. However, in clinical trials, these compounds have been proven to be
either ineffective or cause adverse side effects believed to be due to their non-specific MMP
inhibition.87 The predominant side effect is a musculoskeletal syndrome (MSS) characterized by
pain and immobility in the shoulder joints, arthralgias, contractures in the hands, and an overall
decreased quality of life.88 Consequently, the only drug approved in human medicine for its
effects on MMP inhibition is the tetracycline antibiotic doxycycline, which is used in the
treatment of periodontal disease.88
Several classes of drugs are capable of inhibiting MMPs including corticosteroids,
retinoic acid, chelating agents, bisphosphonates, statins, certain antibiotics, non-steroidal antiinflammatory drugs (NSAIDs), and phosphodiesterase inhibitors.23,88 Glucocorticoids and
retinoic acid have both been shown to inhibit MMP transcription.12,13,38,89,90 Dexamethasone,
triamcinolone, and prednisolone inhibit MMP-1, 2, 3, and 13 in equine chondrocyte cultures.71,91
Chelating agents, N-acetylcysteine, and disodium ethylene diamine tetraacetate (EDTA), are
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known to inhibit MMPs by binding Zn2+ and Ca2+. Both agents are used in the treatment of
ulcerative keratitis.92,93 Bisphosphonates, while developed for use in diseases involving bone
and calcium metabolism, also have MMP inhibitory effects in various diseases including equine
RAO.70,94,95 The mechanism of action of bisphosphonate MMP inhibition is unclear, but is
suggested to involve chelation of cations and down-regulation of mRNA and protein
expression.70 Statins are often used in cardiovascular disease and have been shown to inhibit
MMPs through decreased expression and secretion.96,97 Clarithromycin and erythromycin, both
macrolide antibiotics, have MMP inhibitory effects in cardiac allograft recipients and cultured
smooth muscle cells through decreased MMP expression.98,99
In addition to their antibiotic effects, tetracyclines inhibit MMPs through decreased
transcription, chelation of Zn2+ and Ca2+, and increased degradation of the enzymes.100,101
Doxycycline, a semi-synthetic tetracycline, has been shown to be an effective MMPI in various
tissues and diseases including endothelial cells, pleural fluid, corneal epithelium, cerebral
ischemia, and endotoxemia-induced cardiac dysfunction.102-106 As previously mentioned, it is the
only MMPI approved for human use. In horses, doxycycline is used in the treatment of various
diseases including Potomac horse fever caused by Neorickettsia risticii, a disease associated with
depression, fever, diarrhea, and laminitis.107 It has been reported to cause cardiovascular
collapse and death when administered intravenously (IV) to horses; however, several studies
have demonstrated the safety of oral administration of doxycycline.108-110 Oxytetracycline, a
tetracycline analogue, is used in the horse for its antibiotic properties, but also for the treatment
of flexural deformities in foals. It has been shown to decrease MMP-1 expression in equine
myofibrils.111 Chemically modified tetracyclines have been developed by removing the
antimicrobial portion of the compound; thus, leaving the MMP inhibitory portion.112 Research
suggests that they may be of potential use in horses with RAO.70
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NSAIDs are cyclooxygenase (COX) inhibitors, thus preventing the formation of
eicosanoid inflammatory mediators in the arachidonic acid cascade. They decrease MMP-2 and
MMP-9 activities by decreasing mRNA expression.113,114 Cyclooxygenase-2 increases MMP-2
and MMP-9 expression that can then be decreased in response to both non-selective and selective
NSAIDs.114-117 Other research suggests that NSAIDs up-regulate mRNA expression of
RECK.118 Due to their MMP inhibiting abilities, various NSAIDs are being used to prevent
tumor migration and metastasis in cancer. Although many studies have shown the MMP
inhibitory effects of NSAIDs in other species, there is very little data assessing their ability to
inhibit equine MMPs. Flunixin meglumine is an NSAID that is commonly used in horses for
gastrointestinal pain and inflammation. The only research published do date suggests that in
vitro, flunixin meglumine does not inhibit MMP-2 or MMP-9 obtained from equine cell
culture.91
Phosphodiesterase inhibitors regulate MMP expression by increasing intracellular cAMP
concentrations that disrupt phosphorylation pathways and prevent gene transcription.113,119
Pentoxifylline is a methyl xanthine derivative and phosphodiesterase inhibitor commonly used
for its rheological effects on peripheral vascular disease in people.120 It produces potent antiinflammatory effects through reduction of TNF-α and IL-6 concentrations and enhancement of
the anti-inflammatory cytokine IL-10.121 Pentoxifylline has also been shown to decrease
neutrophil infiltration and activation.119,122 It is used in the horse for its anti-inflammatory
effects in the treatment of endotoxemia and other systemic inflammatory conditions.
1.3 The Systemic Inflammatory Response/Endotoxemia
Systemic inflammatory response syndrome (SIRS) has been defined by the American
Society of Chest Physicians and the Society of Critical Care Medicine as an inflammatory
response that includes more than one of the following clinical manifestations: 1) hyper- or
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hypothermia, 2) tachycardia, 3) tachypnea, or 4) leukocytosis or leucopenia.123 This systemic
response is most often associated with endotoxemia originating from Gram-negative bacteria.
Endotoxin (lipopolysaccharide, LPS) is one of the most potent bacterial toxins known, and is
responsible for inciting the severe inflammatory response seen during endotoxemia in the horse,
as well as other species.124 The microvascular inflammatory response to endotoxin results in
activation of mononuclear phagocytes which release numerous cytokines and enzymes. This
leads to endothelial and leukocyte activation with increased leukocyte and platelet adherence and
microthrombi formation.125 Neutrophils are capable of being activated intravascularly, and are
easily activated in vitro by LPS causing expression of integrin adhesion molecules, decreased
deformability, size variation, and degranulation.126,127 Endothelial cells swell, increasing
capillary and venular permeability resulting in tissue edema. Diapedesis and degranulation of
neutrophils results in further tissue damage and activation of inflammatory mediators. This
systemic inflammatory response begins a vicious cycle in the microcirculation, and if left
unchecked, usually results in cardiac dysfunction, progressive hypotension, coagulopathies, and
organ dysfunction/failure.125
Endotoxin is a component of the outer cell membrane of all Gram-negative bacteria that
can be released during rapid proliferation or cell death. It consists of three components. The
inner lipid A portion is highly conserved among Gram-negative bacteria and imparts the toxic
effects. Each LPS molecule also contains a core oligosaccharide and an outer O-specific
polysaccharide that imparts serotype specificity for different bacterial strains.128
The endotoxin-induced inflammatory process is initiated by the binding of endotoxin to
lipopolysaccharide binding protein (LBP) at the lipid A moiety. Lipopolysaccharide binding
protein acts as a shuttle to facilitate the transport of endotoxin to various cell types including
mononuclear phagocytes, neutrophils, and endothelial cells; however, monocytes and
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macrophages are the principal cells involved in the initial response to endotoxin.129 The
inflammatory response is initiated when LBP transfers endotoxin to the cell surface receptor
CD14. This receptor is present in both a soluble form in the blood and a membranous form on
the surface of monocytes, macrophages, and neutrophils. The soluble form allows other cells
such as endothelial and epithelial cells to react to endotoxin. The endotoxin/LBP/CD14 complex
increases cell sensitivity to endotoxin, but cannot cross the cell membrane to stimulate second
messenger systems or signal transduction pathways.128 The LPS signal is carried intracellularly
by the pattern recognition receptor Toll-like receptor 4 (TLR 4). This occurs with the help of
myeloid differentiation factor 2 (MD2) on the cell surface. Cell stimulation by LPS leads to
activation of the transcription factor nuclear factor κB (NFκB) and the MAPK pathway.
Activation of these pathways ultimately results in the synthesis of various pro- and antiinflammatory mediators responsible for the clinical manifestations of endotoxemia.129
The inflammatory cascade induced by endotoxin includes release of pro-inflammatory
cytokines, chemokines, adhesion molecules, proteolytic enzymes, and acute phase proteins, as
well as production of ecosanoids.125 Tumor necrosis factor-α is the initial mediator of
endotoxin’s effects, and is produced by macrophages in response to LPS.124 This cytokine
typically reaches peak levels in the horse 1-2 hours after LPS exposure.130,131 It is responsible
for a myriad of effects including stimulating the release of other cytokines and neutrophil
activation. Interleukin-6 is produced by monocytic phagocytes, fibroblasts, and endothelial cells,
and is a potent inducer of acute phase proteins.124,129 Interleukin-6 activity is increased in
endotoxemic horses from 30 minutes to 8 hours post-infusion of LPS.130,132 Interleukin-1β is
also released from machrophages in response to LPS. It is a potent attractant for neutrophils, as
well as performing many functions similar to TNF-α.124 Endotoxin has also been shown to upregulate IL-1β and TNF-α mRNA in equine mononuclear cell culture.133
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Endotoxemia also results in the activation and release of proteolytic enzymes, in
particular MMPs. Gelatinolytic activity (MMP-2 and MMP-9) is increased in patients with
clinical Gram-negative sepsis.134 Plasma MMP-9 concentrations are increased between 1 hour
and 8 hours post-infusion of LPS to human volunteers and between 30 minutes and 6 hours after
LPS administration to baboons.134-136 Septic shock non-survivors have higher plasma
concentrations of MMP-9 and greater expression of MMP-9 mRNA compared with survivors,
with a positive correlation between plasma LPS and MMP-9 concentrations.137 Matrix
metalloproteinase-9 activity is increased in the liver, spleen, kidney, brain, heart, and aorta of
mice administered LPS.105,138,139 Endotoxin also stimulates release of MMP-2 in endothelial
cells and rat aorta, as well as MMP-9 in peritoneal macrophages.138,140-142 Interleukin-1β
stimulates the release of MMP-2 from rat aorta.138 Lipopolysaccharide, TNF-α, IL-8, and
granulocyte colony-stimulating factor all stimulate rapid release of MMP-9 from neutrophil
granules.134 Reactive oxygen species released from neutrophil granules help regulate the activity
of vascular MMPs and are generated in response to LPS.143,144 In particular, peroxynitrite, a byproduct of NO release, can activate MMPs and is increased along with NO in LPS-treated
rats.140,145,146 Increases in MMP-9 activity correlate inversely with mean arterial pressure (MAP)
in endotoxemic rats.147 Furthermore, LPS and IL-1β both induce hyporeactivity in rat aorta that
can be ameliorated by doxycycline, a potent MMPI, suggesting that MMPs play an important
role in the cardiovascular effects of endotoxemia.138
In healthy horses, the gastrointestinal tract contains large amounts of endotoxin owing to
the large quantities of Gram-negative bacteria needed for fermentation of food material.129 There
are several mechanisms present to prevent LPS from reaching the systemic circulation during
normal states. Mucosal epithelial cells, the mucous layer covering them, and other resident
bacteria restrict the movement of endotoxin within the intestinal lumen.128 Occasionally in
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healthy animals, small amounts of the toxin escape into the portal circulation. These molecules
are quickly removed by either hepatic macrophages known as Kupfer cells or circulating antiendotoxin antibodies to prevent a systemic inflammatory response. However, under disease
conditions, endotoxin can overwhelm these mechanisms and play a major role in the systemic
inflammatory response in the horse.124
Endotoxemia in the horse most often occurs secondary to compromise of the intestinal
tract barrier. The quantity of endotoxin in the circulation can become so great that it cannot be
sufficiently removed and thus overwhelms the normal protective mechanisms. Endotoxin can
also cross hypoperfused or inflamed intestine, enter the peritoneal cavity, and gain access to the
systemic circulation via the thoracic duct.128
There are many disease processes of the horse that may lead to the development of
endotoxemia. Acute abdominal disease, colitis, post-operative ileus, enteritis, peritonitis,
pleuropneumonia, metritis, and grain overload are all capable of inducing secondary
endotoxemia in the horse. Most commonly, equine endotoxemia results from an acute
gastrointestinal tract disturbance. Endotoxin has been detected in the plasma of approximately
25% of horses admitted to teaching hospitals for acute gastrointestinal tract disease.148
Experimentally, LPS decreases cecal blood flow and increases intestinal permeability, thus
allowing endotoxin access to the systemic circulation.149 In an experimental model of small
intestinal ischemia/reperfusion injury, circulating endotoxin was detected at 60 and 120 minutes
after reperfusion.150 Clinical studies have shown that 50% of horses are endotoxemic during
colic surgery, and that circulating LPS can be detected in a large proportion of horses up to 5
days after colic surgery.151,152
Intravenous infusion of LPS has been used extensively in the past as a method for
inducing experimental endotoxemia. Typically following administration of low-dose LPS (10 –
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35 ng/kg), horses become mildly colicky and develop fever, tachypnea, tachycardia, an initial
neutropenia with a rebound neutrophilia, thrombocytopenia, increased capillary refill time
(CRT), hemoconcentration, and lactic acidosis.130,131,153 Leukopenia is one of the cardinal signs
of endotoxemia and can occur between 30 minutes and 4 hours post-infusion.154,155 Higher doses
of LPS (over 10 µg/kg) have resulted in mucous membrane cyanosis, hyper- and hypoglycemia,
hyper- and hypothermia, and extreme coldness of the lower limbs.156,157
Although experimentally-induced endotoxemia does not exactly replicate or mimic
clinical disease, it allows for investigation of various aspects that cannot be studied or controlled
in the clinical arena. Endotoxemia has been shown to cause decreased gastrointestinal tract
motility in horses, specifically decreased intestinal muscular activity due to edematous
degeneration and coagulative necrosis of smooth muscle cells of the intestinal muscularis layer
and possibly degeneration of the central, autonomic, and myenteric nervous systems.158,159
Lipopolysaccharide stimulates COX-2 activity in equine digital arterial smooth muscle cells.133
Prostaglandin E2 decreases gastric contraction amplitude and rate in endotoxemic ponies.160 This
decrease in gastric activity can be prevented by pre-treatment with phenylbutazone, a known
COX-1 inhibitor.161 Insulin resistance is caused by endotoxemia in humans and rats. In horses,
administration of endotoxin resulted in decreased insulin sensitivity for 24 hours along with a
compensatory pancreatic response.153
One major sequelae to diseases accompanied by endotoxemia in horses is the
development of laminitis. Endotoxin has been detected in both cecal contents and plasma of
horses with experimentally-induced carbohydrate overload (CHO) laminitis, and has been
associated with Obel Grade 3 lameness in this model.162,163 Lactic acid-induced decreases in the
cecal population of Gram-negative bacteria correlates with the over 5 times increase in cecal
fluid endotoxin levels.162,164 Severe compromise of the cecal mucosa found in experimental
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CHO allows numerous toxins, including endotoxin, to enter the circulation and stimulate the
release of pro-inflammatory cytokines, as demonstrated by the increased plasma endotoxin levels
seen in CHO-induced laminitis.163,165 Evidence of endotoxemia including elevated temperature,
tachycardia, and limb edema has also been observed in horses developing laminitis after
accidental CHO.166 Experimentally-induced endotoxemia leads to decreased digital arterial and
venous blood flow, decreased digital laminar blood flow, and decreased coronary band and hoof
wall temperature.131,167 Increases in plasma 5-hydroxytryptamine (5-HT) and thromboxane B2
(TXB2) occur with in vivo administration of LPS and with in vitro stimulation of equine
platelets.131,168 These substances have been suggested as possible vascular mediators in the
development of laminitis.168 Endotoxemia has also been implicated as an important risk factor
for the development of acute laminitis in horses hospitalized for medical or surgical
conditions.169 Despite the association between clinical endotoxemia and laminitis,
experimentally-induced endotoxemia does not reproducibly induce laminitis. Nevertheless, the
clinical occurrence of laminitis subsequent to diseases associated with endotoxemia suggests that
LPS does play a role, either directly or indirectly, in the development of laminitis.
1.4 Equine Laminitis
Acute laminitis is an excruciatingly painful and severely debilitating disease
of the soft tissues of the equine digit. In many instances, it can lead to the separation of the
epidermal and dermal laminae, resulting in rotation and/or sinking of the third phalanx within the
hoof capsule.170 This disease is common to all breeds world-wide and often results in chronic
pain, lameness, and sometimes death. Laminitis is frustrating to both veterinarians and owners
as current therapy consists mainly of NSAIDs and therapeutic shoeing, which are often
ineffective. One of the major reasons for the limited scope of treatment is that the pathogenesis
of laminitis is not fully understood despite years of intense research.
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A recent survey by the American Association of Equine Practitioners (AAEP) found that
equine practitioners believe laminitis is the most important disease afflicting horses and the
number one disease requiring further research efforts and funding.171 This is most likely due to
the prevalence, morbidity and mortality, and economic and emotional costs of the disease, as
well as the incomplete understanding of its pathogenesis. Laminitis is considered one of the
most important diseases in the equine industry with an estimated 15% of horses developing
laminitis during their lifetime, of which 75% of those admitted to referral hospitals eventually
require euthanasia.172 Annual monetary losses related to laminitis have been conservatively
estimated at greater than $13 million associated with its diagnosis, treatment and loss of horses
subsequent to complications.173
In the horse, the distal phalanx (P3, coffin bone) is contained within the hoof capsule, and
is attached to the hoof wall via soft tissue attachments. Theses attachments, or laminae, extend
from the inner surface of the hoof wall to form the primary epidermal (insensitive) laminae
(PEL) and from the periosteum of P3 as primary dermal (sensitive) laminae (PDL). It is
estimated that there are approximately 600 PEL per hoof.174 These epidermal and dermal
laminae interdigitate and, in effect, suspend the distal phalanx within the hoof capsule (Figure
1.2). Both the PEL and PDL have secondary laminae that also interdigitate and increase the
surface area of attachment between the hoof wall and P3.175 A BM separates the avascular
secondary epidermal laminae (SEL) from the vascular secondary dermal laminae (SDL).
Laminin, a glycoprotein, is distributed throughout the BM and is important for the differentiation
and attachment of epidermal basal cells.175 Hemidesmosomes (HD) attach the epidermal basal
cells to the lamina densa of the BM through anchoring filaments.175 The proximal epidermal
laminae located near the coronary band and periople are proliferative, but the majority of the
epidermal laminae are nonproliferative and function to suspend P3.176
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Figure 1.2 – A hoof from a normal horse illustrating the hoof wall (A), epidermal laminae (B),
dermal laminae (C), and third phalanx (D). Note that the third phalanx is parallel to the hoof
wall.
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The medial and lateral palmar digital arteries supply oxygenated blood to the foot. Blood
flows through various arteries on its way to the laminar microvasculature. Each PDL is supplied
by a papillary artery flowing into a capillary bed which feeds the lamina and then passes out by
way of a papillary vein.174 Deoxygenated blood eventually leaves the foot via the medial and
lateral palmar digital veins. Each papillary artery and vein have numerous (approximately
500/cm2) arteriovenous anastomoses (AVAs), or shunts, between them that may regulate hoof
temperature in cold environments.174
During acute laminitis, the laminae are inflamed and may become necrotic and separate.
If this occurs, P3 is able to rotate or sink distally within the hoof capsule leading to intense pain
and hoof structural alteration (Figure 1.3). Consistent histological changes within the laminae
early in laminitis are degradation of the BM and detachment from the epidermal basal cells in
the SEL.83,175 Also, numerous neutrophils accumulate at the SDL tips, many of which have
penetrated the BM and have moved into the SEL.83,177,178
Laminitis may be a primary disease, (e.g. due to excessive concussive force), but most
often occurs secondary to other illnesses. Grain overload, colitis, enteritis, pleuropneumonia,
metritis, colic, and contralateral limb lameness often precede the onset of laminitis.179 With the
exception of contralateral limb lameness, the aforementioned diseases may all be associated with
endotoxemia. Studies have shown that gastrointestinal (GI) disease is the most common problem
noted prior to the onset of laminitis, and that endotoxemia is a significant risk factor for the
development of laminitis.169,180 Although there appears to be an association clinically between
endotoxemia and laminitis, experimentally-induced endotoxemia does not reproducibly result in
laminitis. However, laminitis can be experimentally induced using either a CHO model, a black
walnut extract (BWE) model, or an oligofructose (OF) model.181-183
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Figure 1.3 – A hoof from a horse with chronic laminitis illustrating the hoof wall (A), epidermal
laminae (B), dermal laminae (C), and third phalanx (D). Note that the third phalanx has rotated
distally from the hoof wall, and the epidermal and dermal laminae are thickened.

23

Due to the variable etiologies for the development of laminitis, the pathophysiology
remains elusive. There are several different hypotheses regarding its pathogenesis.184 A
vascular theory hypothesizes that dysfunction of the digital vasculature results in interstitial
edema and ischemia followed by laminar necrosis and separation.185 There is conflicting
evidence as to whether vasodilation or vasoconstriction occurs at the onset of laminitis. Early
work using arteriovenograms to evaluate blood flow before and after CHO indicated that blood
flow in the terminal arch of the foot was significantly decreased or absent after CHO.186 Other
research has suggested that venoconstriction mediated via either ET-1, TXA2, or 5-HT is
responsible for the laminar ischemia.168 Evaluation of Starling forces in horses with CHO and
BWE indicate that increases in capillary pressure owing to increased vascular resistance leads to
interstitial edema within the digit.187,188 Decreased hoof wall temperature, suggesting a decrease
in digital vascular perfusion, and decreased lamellar microvascular blood flow occur during the
developmental phase of carbohydrate overload induced laminitis.189,190 Other studies report
conflicting data. Early data refuted the theory of decreased perfusion suggesting that increased
digital blood flow occurred in the CHO model due to decreased vascular resistance.191
Scintigraphy used to evaluate blood flow following CHO indicated there was no reduction of
blood flow and that flow was significantly increased in the laminae.192 Others have reported that
increases in hoof wall temperature occur at the onset of clinical signs with no prior indication of
decreased blood flow, and that cryotherapy prevented histological evidence of laminitis and
lameness.83,193 It has been suggested that vasodilation occurs initially leading to opening of
AVAs within the digital microvasculature to protect the laminar capillaries from the high
pressures of increased flow. However, this leads to ischemia of the laminar tips if vasodilation is
prolonged as in laminitis.194 Regardless of the initial event, it is generally accepted that vascular
changes are intricately involved in the pathogenesis of laminitis.
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Other research has characterized laminitis as a local manifestation of a systemic
inflammatory response.195 Pro-inflammatory mediators, namely IL-1β, IL-6, IL-8, and COX-2
are up-regulated in the laminae during the early stages of BWE laminitis.196-199 Normal laminae
contain little or no neutrophils or macrophages in the perivascular region of the SDL.178
However, in BWE laminitis, there is an influx of leukocytes, mostly neutrophils, into the dermal
laminae at the onset of leukopenia that increases to significance by the onset of lameness.178
Neutrophil activation is further demonstrated by increases in plasma, laminar, and skin
myeloperoxidase prior to the onset of lameness in BWE laminitis.200
Coinciding with the inflammatory component of laminitis is the theory that intestinal
mediators are released into the circulation that initiate SIRS and activate inflammatory cells to
release cascades of mediators.201 Among these mediators are enzymes that regulate formation
and degradation of the extracellular matrix, especially MMPs. In the horse, MMP-2 and -9 have
been isolated within the laminae of the digit.202 As stated previously, they are members of the
gelatinase family and have the ability to degrade type IV collagen. Hemidesmosomes separate
from the lamina densa due to degradation of anchoring filaments and allow laminar separation to
occur in vitro when explants are exposed to the MMP activator p-aminophenylmercuric acetate
(APMA), a mercurial compound.203 APMA-induced laminar separation can also be prevented by
the MMPI batimastat.204 Laminar explants of horses with acute laminitis have increased
concentrations of MMP-2 and MMP-9.83 Thus, MMP-2 and MMP-9 appear to be associated
with the BM destruction and laminar separation characteristic of acute laminitis. Mungall et al
described an “in vitro laminitis model” in which bacterial broths increased MMP-2 and MMP-9
concentrations and increased laminar separation in equine digital laminar explants.205 Bacterial
proteinases such as thermolysin increase laminar explant separation as well as activate
proMMP-2 and proMMP-9 in vitro.202 This, along with increases in Gram-positive bacteria in
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the cecum of horses during CHO laminitis, led some researchers to believe that Streptococcus
bovis toxins are responsible for the initiation of MMP-associated laminar destruction.205
The roles of MMP-2 and MMP-9 have also been evaluated in vivo. Both enzymes are
activated in laminar tissues of horses with naturally-acquired laminitis when compared to
laminae of normal horses.82 Also, plasma MMP-9 concentrations and transcription of MMP-2 in
laminar tissues are increased during experimentally-induced laminitis using a CHO model.85,206
Recently, increased transcription of MMP-14 in the laminae of horses with OF laminitis has been
reported, which is required for activation of MMP-2.86 As previously mentioned, MMP-9
concentrations are increased in laminar tissue of BWE horses; however, pro and active forms of
MMP-2 are present in both control and BWE horses.84 Serum collagen IV concentrations are
increased in horses with naturally-acquired laminitis suggesting the breakdown of ECM by
MMPs.207
Several inflammatory cells release MMP-9, in particular neutrophils. Activation of
MMPs during laminitis could be associated with leukocyte recruitment and induction of
inflammation. Decreases in circulating leukocytes as well as increases in production of ROS by
leukocytes have been found in horses with BWE laminitis.195 Small amounts of MMP-9 are
produced by keratinocytes and epithelial cells and have been found in normal SEL.208
Neutrophil accumulation within the laminae is followed by increases in MMP-9 concentrations
and mRNA expression in laminar tissues coinciding with the onset of Obel grade 1 lameness,
suggesting that neutrophil infiltration, MMP-9 accumulation, and lameness are linked.84,196
Release of MMP-2 from platelets leads to platelet aggregation, and there is a correlation between
MMP-2 inhibition and decreased platelet aggregation.209 This suggests that MMP-2 may be
involved in increased platelet aggregation and platelet-neutrophil aggregates found in CHO
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laminitis.210 Therefore, the neutrophil infiltration and release of inflammatory mediators within
the digital laminae during laminitis may lead to increased release of both MMP-2 and MMP-9.
Metabolic disturbances are also suggested to precede the development of laminitis.
Starch-rich diets and high fat supplements fed to inactive horses leads to increases in abdominal
adipose tissue and predisposition to the development of a “peripheral Cushing’s syndrome”
characterized by insulin resistance, glucose intolerance, and laminitis.211 Laminitis-prone ponies
are hyperinsulinemic and insulin resistant compared with control ponies.212 Clinical and
histological laminitis can be induced in normal ponies by prolonged hyperinsulinemia with
euglycemia.213 Chronic administration of the glucocorticoid dexamethasone leads to increased
insulin resistance and predisposition for the development of laminitis.214 In vitro, glucose
deprivation induces laminar separation by reducing HD numbers, suggesting a mechanism by
which insulin resistant horses may develop laminitis.203
The exact pathophysiology of acute laminitis is actively being pursued in the equine
scientific community. Although there are still many gaps in the multiple etiologic pathways that
may ultimately result in laminitis, each of the components suggested above most likely plays a
role in the development of this disease. Laminitis of alimentary origin can be used to illustrate
how these components may be interconnected (Figure 1.4) In this model, it is suggested that
altered GI permeability leads to the elaboration of gut-derived substances which are absorbed
into the portal circulation causing profound systemic effects. This leads to local changes within
the digit including vascular, inflammatory, enzymatic, and metabolic effects, each of which can
perpetuate the other, leading to a vicious circle of events. All of the local digital effects result in
laminar structural alterations that can lead to laminar biomechanical weakening. Weakening of
the laminae ultimately results in rotation/sinking of the distal phalanx within the hoof capsule
and the clinical manifestations of acute laminitis.
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Figure 1.4 – A schematic of the events associated with the development of acute laminitis of
alimentary origin.
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While etiologies are varied and the definite pathophysiology of acute laminitis remains
elusive, current methods of treatment remain unchanged. NSAID administration along with
application of frog supports are the cornerstone of therapy, with phenylbutazone being the most
commonly used medication.180 Other medications used include the NSAID flunixin meglumine,
the vasodilators acepromazine, isoxsuprine, and nitroglycerin, and the anti-inflammatory agents
dimethylsulfoxide (DMSO) and pentoxifylline.180,215 Acepromazine administered intravenously
or intramuscularly leads to modest increases in digital arterial blood flow in normal horses.215,216
Isoxsuprine has been reported to improve lameness associated with CHO laminitis when
administered IV, but has no effect on digital blood flow when administered orally.215,217
Nitroglycerin has been shown to both improve and have no effect on digital blood flow.190,218-221
Pentoxifylline has also been shown to have no effect on digital blood flow when administered
orally to normal horses.215 Therapeutic shoeing, deep digital flexor tenotomy, and radical hoof
wall resections are treatments used for cases of chronic laminitis.
The lack of effective treatments for acute laminitis necessitates further investigation of
possible therapeutic agents. The recent elucidation of the suspected role of MMPs in the
pathophysiology of this disease suggests that MMPIs may be effective in its treatment and
warrants their evaluation.
1.5 Summary of Literature and Hypotheses for Present Studies
Matrix metalloproteinases are enzymes responsible for the normal remodeling and
pathologic destruction of the ECM. During inflammation and disease, the increased release and
unregulated activation of MMPs lead to rampant tissue destruction and organ failure. Regulation
of MMPs using exogenous MMPI is a new avenue of exploration for the treatment of various
pathological conditions.
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Endotoxemia incites a systemic inflammatory response characterized by activation of
inflammatory mediator cascades. The increased release and production of MMPs play a
significant role in the pathologic changes associated with this condition. The administration of
endotoxin, the toxic portion of Gram-negative bacteria responsible for initiating SIRS, has been
shown in many species to directly and indirectly induce MMP synthesis. Experimental induction
of endotoxemia in the horse results in increases in various inflammatory mediators; however,
MMP activity has not been investigated.
Acute laminitis in the horse is characterized by breakdown of the BM between the SEL
and SDL and subsequent separation of the laminae within the digit. This is believed to occur
following the proteolytic actions of MMP-2 and MMP-9 on the laminar BM. Therefore,
reductions in MMP activity via MMPIs may be beneficial. The experimental induction of equine
laminitis can be achieved through several methods; however, while necessary, this is costly both
monetarily and emotionally. The development of a non-terminal model of MMP induction in the
horse could be used to assess the effectiveness of MMPIs before evaluating them in
experimentally-induced laminitis. I propose that experimentally-induced endotoxemia can be
used for such a model. The hypotheses of the studies presented in this dissertation include:
Study 1 – Equine neutrophils can be stimulated to release MMP-9 by PMA. The
commercially available human Biotrak MMP-9 Activity Assay can be validated for use with
equine samples.
Study 2 – Incubation of digital laminar explants with endotoxin will significantly
increase medium MMP-2 and MMP-9 concentrations and significantly decrease laminar
structural integrity. The addition of doxycycline, oxytetracycline, flunixin meglumine, and
combinations thereof will significantly decrease medium MMP-2 and MMP-9 concentrations
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and significantly increase laminar structural integrity. Laminar structural integrity will be
inversely related to medium MMP-2 and MMP-9 concentrations.
Study 3 – Intravenous infusion of endotoxin will significantly increase digital venous
plasma MMP-2 and MMP-9 concentrations in healthy adult horses when compared with digital
venous plasma concentrations in horses administered an IV infusion of saline solution. Pretreatment with oral doxycycline, IV oxytetracycline, IV flunixin meglumine, or IV pentoxifylline
will significantly decrease digital plasma MMP-2 and MMP-9 concentrations in healthy adult
horses administered an IV infusion of endotoxin.
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CHAPTER 2. EVALUATION OF MATRIX METALLOPROTEINASE -9 ACTIVITY IN
EQUINE NEUTROPHIL SUPERNATANT USING ZYMOGRAPHY AND AN
ACTIVITY ASSAY
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2.1 Introduction
Matrix metalloproteinases are proteolytic enzymes that not only degrade ECM
components, but also activate various inflammatory mediators and regulate cell-to-cell
interactions.8,10,11 All MMPs are secreted in a latent, pro-enzyme form that usually requires
cleavage for activation.4 Matrix metalloproteinases are required for normal tissue development
and remodeling and play important roles in various human pathological conditions from
neurologic disease to cancer.4,56,59 In recent years, MMPs have been implicated in several equine
diseases, including RAO, OA, tendonitis, corneal ulceration, and laminitis.68,71,77,79,84
The most commonly studied MMPs to date are the gelatinases, MMP-2 and MMP-9.
While proMMP-2 (72 kD) is constitutively expressed by various structural cell types, proMMP-9
(92 kD) is mostly induced during inflammatory states and released from neutrophils.7 Most
other cells do not store MMP-9, and secretion typically follows induction by de novo synthesis;
however, neutrophils accumulate the zymogen within tertiary granules and release large
quantities upon degranulation.7 Neutrophil accumulation has been correlated with MMP-9
activity in several equine diseases, including equine laminitis and arthritis.74,84 Increases in
MMP-2 and MMP-9 concentrations have been found in laminar tissues of both experimentallyinduced and clinically laminitic horses.82,85 Plasma concentrations of MMP-9 are also increased
in horses with CHO laminitis.206
There are several methods available for assessing MMP activity. Gelatin zymography is
the traditional method used for measuring gelatinase activity; however, it is only semiquantitative. ELISAs are quantitative, but can only measure either the pro or active form of
MMPs. An MMP activity assay has been developed which is highly specific and sensitive,
quantitative, and can determine both pro and active forms of the enzymes.
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The purpose of this study was to collect and purify MMP-9 from equine neutrophils for
use as a standard in the validation of the Biotrak MMP-9 Activity Assaya for use with equine
samples. The presence of MMP-9 in the neutrophil supernatant was confirmed by western
blotting using equine granulation tissue as a positive control. Gelatin zymography and the
activity assay were used to evaluate MMP-9 activity in the neutrophil supernatant.
2.2 Materials and Methods
2.2.1 Isolation/Stimulation of Equine Neutrophils – This study was approved by the
Institutional Animal Care and Use Committee of Louisiana State University. Jugular venous
blood was collected (60 ml each) from 9 adult horses into vacutainers containing preservativefree heparin. The blood was mixed with room temperature 0.9% NaCl (saline) at a 1:2 dilution.
The cell suspension was carefully poured onto 10 ml Ficoll-Hypaqueb solution in a 50 ml conical
tube. The tubes were centrifuged at 400 X g for 40 minutes at 20°C. The upper saline and
Ficoll-Hypaque layers were then aspirated, leaving the neutrophil/red blood cell (RBC) pellet.
The pellet was resuspended in 20 ml phosphate buffered saline (PBS). An equal volume of
dextran/saline solution (3% Dextran T-500c in 0.9% saline) was added. The mixture was
incubated in an upright position for approximately 20 minutes at room temperature. The
neutrophil-rich upper layer was aspirated, the cells pelleted by centrifugation at 250 X g for 10
minutes at 5°C, and the pellet resuspended in10 ml of 0.9% saline. Residual RBCs were
removed by subjecting the cells to hypotonic lysis by resuspending the pellet in 20 ml of cold
0.2% NaCl for 30 seconds. Isotonicity was then restored by adding 20 ml of ice-cold 1.6%
NaCl. The cells were centrifuged at 250 X g for 6 minutes at 5°C and the supernatant discarded.
This was repeated until the neutrophil pellet was free of RBCs. The cells were counted and
resuspended in serum-free RPMI medium at a concentration of 1 X 107 cells/ml. The neutrophils
were stimulated to release MMP-9 by incubation with phorbol 12-myristate 13-acetated (PMA) at
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a dose of 50 ng/ml for 30 minutes at 37°C. Following stimulation, the cells were centrifuged at
250 X g for 10 minutes at 5°C, and the supernatant was collected and frozen at -70°C.
2.2.2 Protein Extraction of Equine Granulation Tissue – Protein was extracted from a
sample of equine granulation tissue for use as an equine positive control in western blotting. A
small piece of granulation tissue was frozen in liquid nitrogen and pulverized. The pieces of
tissue were placed into a 15 ml conical tube. Three milliliters of extraction buffer (0.05M Tris,
0.001M NaEDTA, 0.15M NaCl, 20mM phenylmethyl sulfonyl fluoride (PMSF), 5 µg/ml
aprotinin, and 0.5% Triton X-114 at pH 8.0) were added to the conical tube. The mixture was
vortexed and left on ice for 2 hours. The mixture was then centrifuged at 12,000 X g for 30
minutes at 4°C.
2.2.3 Western Blot Analysis of Supernatant MMP-9 – The equine neutrophil
supernatant was concentrated 5-fold (5X) via centrifugation at 8000 rpm for 20 minutes using
Centriprep YM30e tubes. The waste was removed and the tubes centrifuged once more. The 1X
and 5X neutrophil supernatant, equine granulation tissue extraction, and human proMMP-9
standard were diluted 1:2 with 2X sample buffer (0.0625M Tris-HCl, 25% glycerol, 4% SDS,
0.01% bromophenol blue at pH 6.8). Fifteen microliters of each sample and the standard were
added to a commercially available 12% Tris-HCl polyacrylamide gelf and subjected to
electrophoresis for 45 minutes at 200 V. The gel was removed and placed in transblot buffer
(25mM Tris, 192mM glycine, and 20% methanol (v/v) at pH 8.3) for 15 minutes. The gel was
then placed into a blot apparatus and subjected to electrophoresis for 90 minutes at 90 V to
transfer the separated proteins onto blot paper. The blot was allowed to incubate overnight in
10% milk in NET buffer (0.05M Tris, 0.001M NaEDTA, and 0.15M NaCl at pH 7.4). After
incubation, the blot was rinsed in NET buffer for 30 minutes. A polyclonal rabbit anti-human
MMP-9 antibodyg was diluted to 18 µl/ml using 10% milk in NET buffer. The blot was
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incubated with MMP-9 antibody for 1 hour and then rinsed with NET buffer for 15 minutes 4
times. Anti-rabbit IgG + horseradish peroxidase conjugateh diluted in 10% milk in NET buffer
(1:1000) was incubated with the blot for 1 hour. The blot was rinsed again with NET buffer for
15 minutes 4 times. The chromogen, tetramethylbenzidine (TMB), was added to the gel to allow
visualization of the protein bands.
2.2.4 Affinity Chromatographic Purification of Equine MMP-9 – Neutrophils were
collected from 9 additional horses, stimulated with PMA to release MMP-9, and the supernatant
collected as previously described. The supernatant was split into Centriprep YM30 tubes and
centrifuged at 4500 rpm for 1 hour at 4°C. The waste was removed and the tubes refilled with
chromatography starting buffer (0.05M Tris-HCl, 0.5M NaCl, 0.005M CaCl2, 0.05% Brij-35,
and 0.02% NaN3 at pH 7.6) for 3 washes. After washing, the supernatant was further
concentrated to 25X the original concentration.
A 5 ml bed volume of gelatin sepharose beadsi was added to a 10 ml chromatography
column. The column was rinsed with 30 ml of chromatography starting buffer. The 25X
supernatant sample was applied to the column, re-collected, and applied to the column a second
time. Fifteen milliliters of elution buffer (0.05M Tris-HCl, 1M NaCl, 0.005M CaCl2, 0.05%
Brij-35, 0.02 NaN3 and 5% DMSO (v/v) at pH 7.6) were applied to the column, and 1 ml elution
fractions were collected.
2.2.5 Zymographic Analysis of MMP-9 Activity – Zymograms were performed using
commercially available 10% gelatin polyacrylamide gels.j Equine neutrophil supernatant elution
samples, 25X neutrophil supernatant, and pro and active MMP-9k standards were diluted 1:2
with 2X sample buffer (62.5 mM Tris-HCl, 25% glycerol, 4% SDS, and 0.01% bromophenol
blue at pH 6.8). Ten microliters of each sample and 7 µl of the standard were loaded onto the
gels. Following 1 hour of electrophoresis at 166 V, the gels were washed with renaturing buffer
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(2.5% Triton X-100) for 30 minutes and incubated for 16-20 hours at 37˚C in development
buffer (50mM Tris-HCl, 200 mM NaCl, 5 mM CaCl2, and 0.02% Brij-35 at pH 7.5). After
incubation, the gels were stained with 0.25% Coomassie brilliant blue in a mixture of aqueous
50% methanol: 10 % acetic acid (v/v) and destained in aqueous 20% methanol: 10% acetic acid
(v/v). Gelatinolytic activity was detected as transparent bands against a dark blue background.
Relative values in arbitrary units (A.U.) were established for MMP-9 concentrations by digitally
photographing the gels and measuring band intensity and size using Image Jl densitometry
software.
2.2.6 Activity Assay Analysis of MMP-9 Activity – Linear dilutions of equine
neutrophil supernatant elution samples and plasma from normal adult horses were evaluated
using the Biotrak MMP-9 Activity Assay. The assay detects both endogenous levels of active
MMP-9 and total MMP-9 (pro + active) by activating any proMMP-9 in the sample with APMA.
Briefly, samples and human proMMP-9 standards (0, 0.125, 0.25, 0.5, 1, 2, 4, 8, and 16 ng/ml)
were incubated in duplicate in microtiter wells coated with human anti-MMP-9 antibody. Any
MMP-9 present became bound to the wells, and any other components in the samples were
removed by washing. APMA was added to all standards and each sample well designated for
total MMP-9 quantification. A pro detection enzyme was added to each well that was then
cleaved and activated by any MMP-9 present. The activated detection enzyme was then able to
cleave a chromogenic peptide substrate resulting in a color change. The color was read at
405 nm using a spectrophotometer. The concentration of MMP-9 in each sample was
interpolated from a standard curve.
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2.3 Results
2.3.1 Western Blot Analysis of Supernatant MMP-9 – The presence of proMMP-9 was
detected in both the 1X and 5X equine neutrophil supernatants and in the equine granulation
tissue extract (Figure 2.1).
2.3.2 Zymographic Analysis of MMP-9 Activity – All supernatant elutions contained
proMMP-9 (92 kD) and proMMP-9 dimer (220 kD) (Figure 2.2).
2.3.3 Activity Assay Analysis of MMP-9 Activity – A linear MMP-9 standard curve
was produced ranging from 0 – 16 ng/ml (Figure 2.3). MMP-9 was detected in the linearly
diluted equine neutrophil supernatant elutions; however, the assay became saturated at
approximately 4 ng/ml equine MMP-9 (Figure 2.4). No MMP-9 was detected in any equine
plasma sample.
2.4 Discussion
In this study, MMP-9 was successfully harvested from PMA-stimulated equine
neutrophils and verified using western blotting. Neutrophil supernatants were further purified
using affinity chromatography, and gelatin zymography was used to assess MMP-9 activity
present in the eluted supernatant samples. Both the monomeric proMMP-9 (92 kD) and the
dimeric proMMP-9 (220 kD) forms were present. The Biotrak MMP-9 Activity Assay was able
to detect equine MMP-9 in the neutrophil supernatant. However, the activity assay was only
approximately 25% as sensitive for equine MMP-9 compared with human MMP-9, for which the
assay was developed.
There is currently no commercially available equine MMP-9 standard; therefore, MMP-9
was harvested from equine neutrophils. A rabbit anti-human MMP-9 antibody was used to
detect MMP-9 in the equine neutrophil supernatant and equine granulation tissue. Wounds with
granulation tissue are in a state of remodeling and, therefore, should contain large amounts of
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Figure 2.1 – Western blot analysis of concentrated equine neutrophil supernatant (5X), protein
extraction from equine granulation tissue (GrT), and human proMMP-9 (MMP-9) using a rabbit
anti-human MMP-9 antibody. A dark band represents the presence of MMP-9.
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Figure 2.2 – Zymogram of equine neutrophil supernatant purified by affinity chromatography
(AC) and 25X concentrated equine neutrophil supernatant (25X). Clear bands represent the
presence of proMMP-9.
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Figure 2.3 – Human MMP-9 (ng/ml) standard curve produced by the Biotrak MMP-9 Activity
Assay. Color change in the assay is directly proportional to MMP-9 activity and is represented
by the rate of change of absorbance at 405 nm (abs405/h2*1000).
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Figure 2.4 – Concentration of MMP-9 (ng/ml) in linear dilutions of equine neutrophil
supernatant elutions determined by the Biotrak MMP-9 Activity Assay. Color change in the
assay is directly proportional to MMP-9 activity and is represented by the rate of change of
absorbance at 405 nm (abs405/h2*1000).
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MMPs. For this reason, equine granulation tissue was selected as a positive control for the
MMP-9 antibody used in the western blotting. Although the western blot indicated that the 5X
concentrated neutrophil supernatant contained MMP-9, the supernatant was further concentrated
to 25X to ensure that enough MMP was present in the chromatography elution for detection by
the activity assay. The monomeric and disulfide-bonded homodimeric forms of proMMP-9 seen
on the zymogram in the neutrophil supernatant are both physiologic forms of the same enzyme
and have been identified in many different tissues, cell culture supernatants, and biological
fluids.222
PMA-induced neutrophil degranulation occurs by activation of phosphokinase-C and
NADPH-oxidase. Stimulation of equine neutrophils with PMA resulted in significant release of
MMP-9 into the supernatant, confirming previous reports that equine neutrophils store this
enzyme.223 This has significant implications for equine diseases in which the elevated presence
of MMP-9 correlates with neutrophil abundance, such as laminitis, RAO, and arthritis.
Gelatin zymography is the traditional method for assessment of both MMP-2 and
MMP-9. This method is highly sensitive and specific for the gelatinases and quite economical.
However, it is only qualitative or semi-quantitative, as only relative values of MMP activity can
be calculated from densitometry readings. The Biotrak MMP-9 Activity Assay is highly specific
for MMP-9 and equally as sensitive as an ELISA. Like an ELISA, the activity assay is truly
quantitative; however, it is superior due to its ability to determine both pro and active forms of
the enzyme.
Unfortunately, the activity assay had a low sensitivity for equine MMP-9. This may have
been due to the human monoclonal MMP-9 antibody used in the assay, although it reportedly
cross-reacts with mouse and rabbit samples.224 Equine MMP-9 may have similar but not
identical epitopes as human MMP-9. Thus, all of the equine MMP-9 may not have been bound
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by the antibody, decreasing the amount of enzyme that could be detected. Components of the
chromatography elution buffer may also have been interfering with the assay.
Although the activity assay was able to measure MMP-9 in the purified neutrophil
supernatant, it could not detect any MMP-9 in the normal equine plasma samples. Normal
human plasma contains 4.4 – 27.2 ng/ml MMP-9, as measured by the activity assay.224 It would
seem likely that normal equine plasma would also contain measurable MMP-9 concentrations.
The incubation time was extended to increase the sensitivity of the assay, but MMP-9 was never
detected in any equine plasma samples. This seems most likely due to the lowered sensitivity of
the activity assay for equine MMP-9. Also, other components of the plasma, such as
endogenous inhibitors, may have been preventing the antibody from binding MMP-9 in the
samples.
Due to the high cost of the activity assay and the time already invested in its assessment,
any further evaluation for its use with equine samples was forgone. Supernatant from an equine
tumor cell line had also been collected for evaluation of the Biotrak MMP-2 Activity Assay;
however, it was also aborted. Gelatin zymography was chosen instead for MMP-2 and MMP-9
evaluation of all equine samples in the following studies.
2.5 Product Information
a

Biotrak MMP-9 Activity Assay System RPN2634, Amersham Biosciences, Pascataway, NJ

b

c

Ficoll-Paque Plus 17-1440-02 , GE Healthcare Biosciences Corp, Pascataway, NJ

Dextran T-500, Amersham Biosciences, Pascataway, NJ

d

Phorbal 12-myristate 13-acetate P1585, Sigma-Aldrich, St. Louis, MO

e

Centriprep YM-30 4322, Millipore Corporation, Billerica, MA

f

12% Tris-HCl Ready Gel 161-1156, Bio-Rad Laboratories, Hercules, CA

g

MMP-9 Ab-10 RB-1590-P1, Lab Vision, Thermo Scientific, Freemont, CA
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h

Goat anti-rabbit IgG (H+L) TR-001-HR, Lab Vision, Thermo Scientific, Freemont, CA

i

Gelatin Sepharose 4B 17-0956-01, GE Healthcare Biosciences Corp, Pascataway, NJ

j

10% Gelatin Ready Gel 161-116, Bio-Rad Laboratories, Hercules, CA

k

l

MMP-9 Proenzyme PF038 and MMP-9 Human Recombinant PF024, Calbiochem, La Jolla, CA

Image J, U.S. National Institutes of Health, Bethesda, MD
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CHAPTER 3. MATRIX METALLOPROTEINASE ACTIVITY AND STRUCTURAL
INTEGRITY OF EQUINE DIGITAL LAMINAR EXPLANTS EXPOSED TO
ENDOTOXIN AND MMP INHIBITORS
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3.1 Introduction
Endotoxin is a cellular membrane component of all Gram-negative bacteria that is
responsible for inciting a systemic inflammatory response. It is released following bacterial cell
death or rapid proliferation, and is usually removed from the circulation by hepatic Kupfer cells
or anti-endotoxin antibodies.124 However, during certain diseases, large amounts of endotoxin
can overwhelm normal defense mechanisms and gain access to the systemic circulation resulting
in the activation of multiple inflammatory cascades.128
Matrix metalloproteinases are endopeptidases that degrade ECM proteins and regulate
various cell-cell and cell-matrix interactions.4 They are involved in normal tissue homeostasis,
but are most active during inflammation and disease.8 The enzymes are secreted in a proenzyme, or zymogen, form that must be cleaved for activation.225 The gelatinases, MMP-2 and
MMP-9, degrade denatured collagen, or gelatin, as well as other components of the ECM. While
MMP-2 is constitutively expressed by various structural cell types such as fibroblasts and
endothelial cells, MMP-9 is mostly expressed by inflammatory cells, in particular neutrophils.7
Endotoxin can stimulate the release of MMP-2 and MMP-9 from various cells and tissues in
vitro.138,140,141
Laminitis is an excruciatingly painful and often life-threatening disease of the equine
digit that occurs when the epidermal and dermal laminar attachments within the foot become
inflamed and, in severe cases, fail. Histopathological evaluation of acutely laminitic horses have
shown that epidermal laminar necrosis and disintegration of the laminar basement membrane are
primary lesions.226,227 Recent studies have suggested that activation of MMPs within the digit is
responsible for the laminar separation.206 Both MMP-2 and MMP-9 have been localized to the
equine digit. Several studies have found increased expression of both MMP-2 and MMP-9 in
laminar tissues during experimentally-induced and naturally-acquired laminitis.82,85
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Matrix metalloproteinase inhibitors are currently being studied in human medicine as
potential therapeutic agents for many MMP-associated diseases such as rheumatoid arthritis,
cardiovascular disease, and cancer.56,58,60 Tetracyclines down-regulate expression of MMP-2 and
MMP-9, and may also prevent activation of the zymogen forms.23,88 Doxycycline, a semisynthetic tetracycline, has been shown to be an effective MMPI in various tissues and diseases
including endothelial cells, pleural fluid, corneal epithelium, cerebral ischemia, and
endotoxemia-induced cardiac dysfunction.102-106 Oxytetracycline, a tetracycline analogue, has
been shown to decrease MMP-1 expression in equine myofibrils.111 NSAIDs also inhibit
MMP-2 and MMP-9 through decreased transcription.114

Due to the apparent involvement of

MMPs in equine laminitis, MMPIs may be beneficial in preventing or lessening the laminar
destruction associated with this disease.
The purpose of this study was to evaluate the ability of doxycycline, oxytetracycline, and
flunixin meglumine to inhibit equine MMPs in vitro. Endotoxin was used to induce MMP-2 and
MMP-9 in equine laminar explants. The structural integrity of the explants was assessed using a
mechanical testing device. The culture medium was analyzed for MMP activity using gelatin
zymography.
3.2 Materials and Methods
3.2.1 Horses – This investigation was approved by the Institutional Animal Care and Use
Committee of Louisiana State University. Laminar tissues were harvested from horses
undergoing euthanasia for unrelated research projects. Twelve clinically healthy, adult horses of
varying sex (6 mares, 6 geldings) and breed (4 Thoroughbreds, 4 Paso Finos, 3 Peruvian Pasos,
and 1 Quarter Horse), ranging in age from 4 to 21 years old (median, 12 years) were used for this
study. The horses were deemed to be free of medical problems related to inflammatory diseases,
endotoxemia, or diseases of the digit as determined through complete physical examination,
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complete blood count, lameness examination including hoof testing, and radiographic evaluation
of the digit.
3.2.2 Experimental Design – Laminar explants were harvested from both forefeet of
each horse and were used for 3 separate studies. For each study, explants were incubated and
stimulated in triplicate with various treatments for 24 hours at 37°C. After incubation, the
medium was collected from each explant and frozen at -70°C until analyses for MMP activity
were performed. The remaining explants were then subjected to biomechanical testing for
assessment of structural integrity. Treatments for each of the studies consisted of the following.
Study 1: (1) medium (control); (2) LPSa (E. coli O55:B5)100 ng/ml; (3) LPS + doxycyclineb
(DOXY) 10 ng/ml; (4) LPS + DOXY 100 ng/ml; (5) LPS + DOXY 1 µg/ml; and (6) LPS +
DOXY 10 µg/ml. N = 8 horses were used for this study. The LPS 100 ng/ml dose for explants
stimulation was determined through preliminary data.
Study 2: (1) medium (control); (2) LPS 100 ng/ml; (3) LPS + oxytetracyclinec (OXY) 100
ng/ml; (4) LPS + OXY 1 µg/ml; (5) LPS + OXY 10 µg/ml; and (6) LPS + OXY 100 µg/ml. N =
8 horses were used for this study.
Study 3: (1) medium (control); (2) LPS 100 ng/ml; (3) LPS + flunixin meglumined (FLU) 8
ng/ml; (4) LPS + FLU + OXY 100 ng/ml; and (5) LPS + FLU + DOXY 100 ng/ml. N = 6 horses
were used for this study.
3.2.3 Harvesting of Explants – The laminar explants were harvested using a
modification of the methods described by Pollitt.205 Immediately following euthanasia with
sodium pentobarbitale (100 mg/kg, IV), both forefeet were removed just distal to the
metacarpophalangeal joint. Each hoof was then trimmed proximally and caudally with a band
saw to facilitate further cutting. The hooves were scrubbed with an antibacterial disinfectant and
the solar surface pared with a hoof knife prior to transecting. Using a table saw sterilized with
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disinfectant, the outer ¼ of either the medial or lateral aspect of the hoof was removed in a
sagittal plane. Five more sagittal cuts were made to create five 6-mm slices of the digit. The
slices were rinsed and placed in a sterile saline solution. A small diamond band saw was used to
cut 6 mm X 6 mm blocks of laminar tissue from each slice consisting of the hoof wall, epidermal
laminae, dermal laminae, and distal phalanx (Figure 3.1). The laminar explants were then
incubated in Dulbecco’s Modified Eagles Mediumf (DMEM) supplemented with piperacilling
(64 µg/ml), tazobactamh (8 µg/ml), amikacini (5 µg/ml), and nystatinj (100 U/ml) and stimulated
with the treatments described above at 37˚ C in humidified air supplemented with 5% CO2.
3.2.4 Instron Biomechanical Testing – An Instronk biomechanical testing device was
used to determine the structural integrity of each laminar explant. Pneumatic clamps were
securely affixed to the hoof wall and to the bone of each segment and mounted in the testing
frame (Figures 3.2 and 3.3). Segments were loaded at a constant elongation rate of 25
mm/second until failure. Data were collected at 20 Hz by analog/digital conversion and stored.
The site of failure was recorded and confirmed with light microscopy of specimens. For each
segment examined, stress-strain curves were generated and used to derive the maximum load to
failure.
3.2.5 Zymographic Analyses of MMP Activities – All zymograms were performed
using commercially available 10% gelatin polyacrylamide gels.l Medium samples and pro and
active MMP-2m and MMP-9n standards were diluted 1:2 with 2X sample buffer (62.5 mM TrisHCl, 25% glycerol, 4% SDS, and 0.01% bromophenol blue at pH 6.8). Ten microliters of each
sample and 7 µls of each standard were loaded onto each gel. Following 1 hour of
electrophoresis at 166 V, the gels were washed with renaturing buffer (2.5% Triton X-100) for
30 minutes and then incubated for 16-20 hours at 37˚C in development buffer (50mM Tris-HCl,
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Figure 3.1 – Example of a laminar explant consisting of hoof wall (A), epidermal laminae (B),
dermal laminae (C), and distal phalanx (D).
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Figure 3.2 – A laminar explant mounted in the Instron biomechanical testing device.
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Figure 3.3 – A closer view of a laminar explant mounted in the pneumatic clamps of the Instron
biomechanical testing device.
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200 mM NaCl, 5 mM CaCl2, and 0.02% Brij-35 at pH 7.5). After incubation, the gels were
stained with 0.25% Coomassie brilliant blue in a mixture of aqueous 50% methanol: 10 % acetic
acid (v/v) and destained in aqueous 20% methanol: 10% acetic acid (v/v). Gelatinolytic activity
was detected as transparent bands against a dark blue background. Relative values in arbitrary
units (A.U.) were established for MMP-9 concentrations by digitally photographing the gels and
measuring band intensity and size using Image Jo densitometry software.
3.2.6 Statistical Analyses – All data were tested using the Shapiro-Wilk statistic and
found to have normal distributions. Normally distributed variables were analyzed using an
ANOVA and post-hoc comparisons were made using least squares means. Data were
summarized and graphed as mean ± SEM. Correlations between Instron data and MMP
zymography data were assessed using the Pearson correlation coefficient. A p ≤ 0.05 was
considered significant for all data. SASp statistical software was used for all statistical analyses.
3.3 Results
3.3.1 Instron Biomechanical Testing – In Study 1, LPS + DOXY 1 µg/ml (68.33 ±
4.42) explants had significantly greater load to failure than LPS (59.28 ± 3.09) and LPS +
DOXY 10 ng/ml (58.33 ± 4.06) explants. Explants treated with LPS + DOXY 100 ng/ml (67.54
± 3.43) were also significantly stronger than those treated with LPS + DOXY 10 ng/ml (Figure
3.4). There were no significant differences between control explants and any treatment group. In
Study 2, LPS + OXY 100 ng/ml (74.49 ± 6.19) explants had significantly greater load to failure
than LPS (60.32 ± 3.05) explants (Figure 3.4). There were no significant differences between
control explants and any treatment group.

In Study 3, there were no significant differences

between any explants in any group (Figure 3.4).
3.3.2 Zymographic Analyses of MMP Activities – Lucent bands of enzyme activity
corresponding to proMMP-2 (72 kD) and proMMP-9 (92 kD) were detected in all laminar
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explants medium samples. The active forms of MMP-2 (66 kD) and MMP-9 (83 kD) were not
detected. In study 1, proMMP-2 concentrations were significantly lower in LPS + DOXY 100
ng/ml (0.183 ± 0.010), LPS + DOXY 1µg/ml (0.177 ± 0.011), and LPS + DOXY 10 µg/ml
(0.143 ± 0.010) explants medium compared with control (0.214 ± 0.019), LPS (0.231 ± 0.023),
and LPS + DOXY 10 ng/ml (0.222 ± 0.020) explants medium (Figure 3.5). ProMMP-9
concentrations were significantly lower in LPS (0.157 ± 0.013), LPS + DOXY 10 ng/ml (0.165 ±
0.010), LPS + DOXY 100 ng/ml (0.156 ± 0.011), LPS + DOXY 1 µg/ml (0.142 ± 0.013), and
LPS + DOXY 10 µg/ml (0.125 ± 0.011) explants medium compared with control (0.190 ± 0.015)
explants medium. Furthermore, LPS + DOXY 10 µg/ml medium had significantly lower
proMMP-9 concentrations than LPS and LPS + DOXY 10 ng/ml medium (Figure 3.5).
In Study 2, proMMP-2 concentrations were significantly lower in LPS + OXY 100 ng/ml
(0.164 ± 0.012) and LPS + OXY 1 µg/ml (0.191 ± 0.015) explants medium compared with
control (0.222 ±0.020) and LPS (0.246 ± 0.024) explants medium (Figure 3.6). ProMMP-9
concentrations were significantly lower in LPS (0.158 ± 0.011), LPS + OXY 100 ng/ml (0.124 ±
0.010), LPS + OXY 1 µg/ml (0.152 ±0.013), LPS + OXY10 µg/ml (0.137 ± 0.008), and LPS +
OXY 100 µg/ml (0.114 ±0.007) explants medium compared with control (0.191 ± 0.015)
explants medium. Furthermore, LPS + OXY 100 ng/ml and LPS + OXY100 µg/ml medium had
significantly lower proMMP-9 concentrations than LPS and LPS + OXY 1µg/ml medium
(Figure 3.6).
In Study 3, proMMP-2 concentrations were significantly lower in LPS + FLU + OXY
(0.199 ± 0.014) explants medium compared with control (0.285 ± 0.030) and LPS (0.320 ±
0.031) explants medium. Medium from explants treated with LPS + FLU (0.244 ± 0.018) and
LPS + FLU + DOXY (0.244 ± 0.022) also had significantly lower proMMP-2 concentrations
than medium from explants treated with LPS (Figure 3.7). ProMMP-9 concentrations were
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significantly lower in LPS + FLU (0.127 ± 0.012) and LPS + FLU + DOXY (0.130 ± 0.010)
explants medium compared with control (0.175 ± 0.016) and LPS (0.162 ± 0.012) explants
medium (Figure 3.7).
3.3.3 Correlations Between Laminar Integrity and MMPs – Laminar explant
maximum load to failure had a – 20.6% correlation with proMMP-2 concentrations in the
medium. This was significant at p < 0.001. There was no correlation between medium
proMMP-9 concentrations and explant maximum load to failure.
3.4 Discussion
The MMPIs doxycycline and oxytetracycline increased the structural integrity of equine
digital laminar explants; however, flunixin meglumine had no effect. Doxycycline,
oxytetracycline, and flunixin meglumine all decreased MMP-2 and MMP-9 release from equine
digital laminar explants to varying degrees. Structural integrity and MMP-2 medium
concentrations were negatively correlated, but MMP-9 had no correlation with explant strength.
Hemidesmosomes attach epidermal basal cells to the lamina densa of the BM separating
the epidermal and dermal laminae within the digit. Pollitt et al found that degradation of the
BM, loss of HDs, and detachment of epidermal basal cells are early pathologic events in acute
laminitis.177,227 Mungall et al previously described an “in vitro laminitis model” in which
bacterial broths increased MMP-2 and MMP-9 concentrations and increased laminar separation
in equine digital laminar explants.205 Bacterial proteinases such as thermolysin increase laminar
explant separation as well as activate proMMP-2 and proMMP-9 in vitro.202 Glucose deprivation
induces laminar separation in vitro by reducing HD numbers.203 Hemidesmosomes separate
from the lamina densa owing to degradation of anchoring filaments and allow laminar separation
when explants are exposed to the MMP activator APMA, a mercurial compound.203 Thus,
MMP-2 and MMP-9 appear to be associated with BM destruction and laminar separation.
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Figure 3.4 – Mean (± SEM) maximum loads to failure (Newtons, N) for laminar explants in
Study 1, Study 2, and Study 3 incubated with medium (CONTROL), LPS (LPS), LPS +
doxycycline (DOXY), LPS + oxytetracycline (LPS + OXY), LPS + flunixin meglumine (LPS +
FLU), LPS + flunixin meglumine + oxytetracycline (FLU + OXY), or LPS + flunixin meglumine
+ doxycycline (LPS + FLU + DOXY). Treatment groups with like letters are not significantly (p
≤ 0.05) different.
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Figure 3.5 – Mean (± SEM) proMMP-2 and proMMP-9 band intensities (arbitrary units, AU) in
the medium of laminar explants in Study 1 incubated with medium (CONTROL), LPS (LPS), or
LPS + doxycycline (DOXY). Treatment groups with like letters are not significantly (p ≤ 0.05)
different.
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Figure 3.7 – Mean (± SEM) proMMP-2 and proMMP-9 band intensities (arbitrary units, AU) in
the medium of laminar explants in Study 3 incubated with medium (CONTROL), LPS (LPS),
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Incubation of laminar explants with E. coli bacterial broth has been reported to induce
laminar separation.205 In the study described here, stimulation of explants with E. coli endotoxin
caused a decrease in the strength of explants compared with controls, however, this was not a
significant decrease. Explants in previous studies were incubated for 48 hours, but explants in
this study were only incubated for 24 hours. The incubation time was shortened due to the
possible tissue deterioration that may begin to occur by 48 hours. Perhaps the decreased
incubation time did not allow for maximum stimulation by endotoxin.
The addition of the MMPIs doxycycline or oxytetracycline significantly increased
laminar explant integrity compared with endotoxin alone, suggesting that MMP inhibition may
play a role in preventing laminar separation. This is further supported by significantly decreased
MMP-2 and MMP-9 concentrations in the medium of explants exposed to doxycycline and
oxytetracycline compared with endotoxin alone. Decreases in MMP-2 medium concentrations
were also correlated with increases in explant strength.
Incubation of explants with flunixin meglumine had no effect on explant strength
although significant decreases in both MMP-2 and MMP-9 medium concentrations were
observed. The combination of flunixin meglumine and oxytetracycline further decreased
MMP-2 concentrations. This is in agreement with other reports of MMP-2 and MMP-9
inhibition mediated by NSAIDs.115,117
The response of the laminar explants to endotoxin stimulation was different from that
previously reported. Several cell types and tissues produce increased concentrations of MMP-2
and -9 when stimulated with endotoxin, such as endothelial cells, leukocytes, astrocytes, synovial
cells, and aorta.134,138,140-142,228,229 In the present study, MMP-2 concentrations in endotoxintreated explants were only slightly greater than controls and endotoxin induced a significant
decrease in MMP-9 concentrations. This in vitro laminar explant model may not be suitable for
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extrapolating the effects of endotoxin on MMP-9 activity. Unlike MMP-2 which is expressed
constitutively in tissues, MMP-9 is predominantly released by activated neutrophils.7 Several
studies have shown that MMP-9 and neutrophils are either present at very low levels, or
completely absent from normal equine digital laminar tissue.84,178 The isolated environment of
the laminar explant would seemingly allow more significant changes to be seen in MMP-2
activity compared to MMP-9, as the majority of MMP-9 activity would come from the small
number of neutrophils present in the hoof at the time of tissue collection. There are no reports of
LPS-induced decreases in MMP-9 activity. This is a novel observation, and cannot be explained.
The results of this in vitro study suggest that doxycycline, oxytetracycline, and flunixin
meglumine all have MMP inhibitory effects of varying degrees within the equine digit. Of the
three, oxytetracycline appears to have the greatest effect and the most potential for use as an
MMPI in the horse for the treatment/prevention of laminitis.
3.5 Product Information
a

Lipopolysaccharide from E. coli O55:B5 L2880, Sigma-Aldrich, St. Louis, MO

b

c

Doxycycline hyclate, Ranbaxy Pharmaceuticals, Princeton, NJ

Liquamicin LA-200, Pfizer Animal Health, St. Louis, MO

d

Banamine, Schering-Plough Animal Health, Union, NJ

e

Beuthanasia-D Special, Schering-Plough Animal Health, Union, NJ

f

DMEM – high glucose D6429, Sigma-Aldrich, St. Louis, MO

g

Piperacillin sodium salt P8396, Sigma-Aldrich, St. Louis,MO

h

Tazobactam sodium salt T2820, Sigma-Aldrich, St. Louis, MO

i

Amiglyde-V, Fort Dodge Animal Health/Wyeth, Madison, NJ

j

Nystatin 194534, MP Biomedicals, Solon, OH

k

Instron, Norwood, MA
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l

10% Gelatin Ready Gel 161-1167, Bio-Rad Laboratories, Hercules, CA

m

MMP-2 Proenzyme PF037 and Active PF023, Calbiochem, La Jolla, CA

n

MMP-9 Proenzyme PF038 and Human Recombinant PF024, Calbiochem, La Jolla, CA

o

Image J, U.S. National Institutes of Health, Bethesda, MD

p

SAS v 9.0, SAS Institute, Cary, NC
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CHAPTER 4. MATRIX METALLOPROTEINASE ACTIVITY IN THE DIGITAL
CIRCULATION OF HORSES FOLLOWING AN INTRAVENOUS INFUSION OF
ENDOTOXIN AND PRE-TREATMENT WITH MATRIX METALLOPROTEINASE
INHIBITORS
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4.1 Introduction
Systemic inflammatory response syndrome occurs when inflammation is accompanied by
more than one of the following: 1) hyper- or hypothermia, 2) tachypnea, 3) tachycardia, and 4)
leukocytosis or leukopenia.123 In equine patients with gastrointestinal tract disease or Gramnegative sepsis, endotoxemia initiates a systemic inflammatory response by activating various
inflammatory cascades involving cytokine induction and leukocyte activation, thereby inducing
fever, tachycardia, and neutropenia.129
Matrix metalloproteinases are ECM proteases that are most active during inflammation
and disease.8 Various structural cells constitutively express MMP-2; however, MMP-9 is mostly
expressed by inflammatory cells, in particular neutrophils.7 Both enzymes have been implicated
in various disease processes including endotoxemia.56,59,135 In humans, MMP-9 is increased in
patients with septic shock as well as experimental endotoxemia.134,136,137
Equine laminitis is an excruciatingly painful disease involving the dermal and epidermal
laminae of the equine foot. Recent theories suggest that intestinal mediators initiate SIRS; thus,
activating inflammatory cells to release cascades of mediators, including MMPs.201 Increased
MMP activity within the laminae results in loss of laminar integrity and may lead to the
development of laminitis.206 Several studies have found increased expression of both MMP-2
and MMP-9 in laminar tissues during experimentally-induced and naturally-acquired laminitis,
as well as increased plasma MMP-9 concentrations.82,85,206
Several classes of drugs have MMP inhibitory effects including tetracyclines, retinoic
acids, corticosteroids, NSAID, and phosphodiesterase inhibitors.23,88 Tetracyclines have been
shown to down-regulate expression of MMP-2 and MMP-9, and may also prevent activation of
the zymogen forms.112 Doxycycline significantly reduces MMP-9 activity in vitro and in vivo in
a mouse endotoxemia model.102-106 In horses, doxycycline is used in the treatment of Potomac
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horse fever caused by Neorickettsia risticii, a disease associated with depression, fever, diarrhea,
and laminitis.107 Anecdotally, clinicians report that horses suffering from Potomac horse fever
that are treated with doxycycline develop laminitis less frequently than those treated with other
drugs. Oxytetracycline, a tetracycline analogue, is used in the horse for its antibiotic properties,
but also for treatment of flexural deformities in foals via MMP-1 inhibition.111 There are no
other reports of MMP inhibition in horses by oxytetracycline.
Both NSAIDs and phosphodiesterase inhibitors decrease MMP-2 and MMP-9 activities
by decreasing mRNA expression.113,114 Flunixin meglumine is an NSAID that is commonly used
in horses for gastrointestinal pain and inflammation. Pentoxifylline, a phosphodiesterase
inhibitor, is used in the horse for its anti-inflammatory effects in the treatment of endotoxemia
and other systemic inflammatory conditions. The effects of flunixin meglumine and
pentoxifylline on in vivo MMP inhibition in the horse have not been investigated.
Due to the apparent involvement of MMPs in equine laminitis, MMPIs may be beneficial
in preventing or lessening the laminar destruction associated with this disease. In Chapter 3,
LPS-induced MMP activity was inhibited in equine laminar explants in vitro by doxycycline,
oxytetracycline, and flunixin meglumine. The purpose of this study was to determine if the
administration of endotoxin would increase plasma MMP-2 and/or MMP-9 concentrations in the
horse. Experimentally-induced endotoxemia was then used as an in vivo model of MMP
induction for evaluating potential MMPIs in the horse, including doxycycline, oxytetracycline,
flunixin meglumine, and pentoxifylline.
4.2 Materials and Methods
4.2.1 Horses – This study was approved by the Institutional Animal Care and Use
Committee of Louisiana State University. Twenty-nine clinically healthy, adult horses of
varying sex (11 mares, 18 geldings) and breed (17 Thoroughbreds, 8 Quarter Horses, 3 American
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Paint Horses, and 1 Arabian), ranging in age from 3 to 19 years old (median, 7 years), and
weighing from 379 to 560 kg (median, 491 kg) were used for this study. The horses were
deemed to be free of medical problems related to inflammatory diseases, endotoxemia, or
diseases of the digit as determined by complete physical examination, complete blood count,
lameness examination including hoof testing, and radiographic evaluation of the digit.
4.2.2 Instrumentation – On the morning of the study, horses were placed into stocks and
intravenous catheters were placed percutaneously following routine aseptic preparation of the
skin and subcutaneous infiltration of a local anesthetic. A 14-gauge, 13.3-cm Teflon catheter
was inserted into the left jugular vein for administration of saline solution, LPS, oxytetracycline,
flunixin meglumine, or pentoxifylline. A 20-gauge, 5.1-cm Teflon catheter was inserted into the
left lateral palmar digital vein for blood collection.
4.2.3 Experimental Design – This investigation consisted of 2 studies. Study 1
determined if the administration of LPS could induce MMPs in the digital circulation of the
horse. Study 2 used the MMP induction model developed in Study 1 to evaluate the
effectiveness of several MMPI in the horse.
Study 1 – Horses were randomly allocated into either a control group (n=5) which received
saline solution or a treatment group (n=5) which received LPS. Control horses were
administered 1 L 0.9% saline solution IV over 30 minutes. E. coli 055:B5 LPSa was
administered IV at a dosage of 35 ng/kg in 1 L 0.9% saline solution over 30 minutes.
Study 2 – Horses were randomly allocated into one of the following treatment groups which
received either doxycyclineb (n=5) at 10 mg/kg via nasogastric tube, oxytetracyclinec (n=5) at 20
mg/kg IV, flunixin meglumined (n=5) at 1.1 mg/kg IV, or pentoxifyllinee (n=4) at 8.5 mg/kg IV
in 1L 0.9% saline solution over 30 minutes in addition to LPS. The MMPI treatments were
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administered every 12 hours beginning 12 hours prior to LPS administration. Horses in these
groups were compared with horses that received LPS in Study 1.
For both studies, baseline (T = 0) clinical variables were recorded and digital venous
blood samples were collected into heparinized tubes immediately prior to infusion of LPS or
saline solution. After administration of LPS or saline solution, clinical parameters were recorded
and digital venous blood samples were collected at T = 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0,
16.0, and 24.0 hours. The blood samples were centrifuged for 10 minutes at 2,000 rpm, and the
plasma collected and stored in 1 ml aliquots at -70˚C until analyses for MMP activities were
performed. The IV catheters were removed 24 hours after LPS or saline solution administration.
The horses were observed for an additional 24 hours and returned to pasture.
4.2.4 Clinical Signs of Disease – Heart rate (beats/min), respiratory rate (breaths/min),
rectal temperature (°F), mucous membrane color, CRT (seconds), and behavior were monitored
and recorded at the above mentioned times.
4.2.5 Zymographic Analyses of MMP Activities – All zymograms were performed
using commercially available 10% gelatin polyacrylamide gels.f Digital venous plasma samples
were diluted 1:10 with buffer (25mM Tris, 192 mM glycine, and 0.1% SDS at pH 8.3). The
diluted plasma samples, as well as pro and active MMP-2g and MMP-9h standards, were diluted
1:2 with 2X sample buffer (62.5 mM Tris-HCl, 25% glycerol, 4% SDS, and 0.01% bromophenol
blue at pH 6.8). Ten microliters of each sample and 7 µl of each standard were loaded onto each
gel. Following 1 hour of electrophoresis at 166 V, the gels were washed with renaturing buffer
(2.5% Triton X-100) for 30 minutes and then incubated for 16-20 hours at 37˚C in development
buffer (50mM Tris-HCl, 200 mM NaCl, 5 mM CaCl2, and 0.02% Brij-35 at pH 7.5). After
incubation, the gels were stained with 0.25% Coomassie brilliant blue in a mixture of aqueous
50% methanol: 10 % acetic acid (v/v) and destained in aqueous 20% methanol: 10% acetic acid
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(v/v). Gelatinolytic activity was detected as transparent bands against a dark blue background.
Relative values in arbitrary units (A.U.) were established for MMP concentrations by digitally
photographing the gels and measuring band intensity and size using Image Ji densitometry
software.
4.2.6 Statistical Analyses – All data were tested using the Shapiro-Wilk statistic and
found to have normal distributions. Normally distributed variables were analyzed using a mixedeffects ANOVA with horse as a random variable. Post-hoc comparisons were made using least
squares means. P ≤ 0.05 was considered significant. Data were summarized and graphed as
mean ± SD. SASj statistical software was used for all statistical analyses.
4.3 Results
4.3.1 Clinical Signs of Disease – The mean values for heart rate, rectal temperature, and
respiratory rate for each group are listed in Table 4.1. Heart rate and rectal temperature did not
significantly change from baseline (T=0) in horses receiving saline solution; however,
respiratory rate increased significantly and remained elevated after 0.5 hours. Tachycardia,
increased rectal temperature, and mild colic occurred in all horses receiving LPS alone or in
combination with an MMPI, consistent with a systemic inflammatory response. Horses
receiving LPS alone or in combination with an MMPI had modest, intermittent increases in
respiratory rate. The administration of LPS significantly increased heart rate from 0.5 through
6.0 hours and rectal temperature from 1.5 through 6.0 hours compared with the administration of
saline. Horses receiving either oxytetracycline or flunixin meglumine had decreased heart rates
and rectal temperatures compared with horses receiving only LPS. Alterations in clinical
variables returned to normal by 24.0 hours in all horses.
4.3.2 Zymographic Analyses of MMP Activities – Lucent bands of enzyme activity
corresponding to proMMP-2 (72 kD) and proMMP-9 (92 kD) were detected in all digital venous
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Table 4.1 – Mean heart rates (HR, beats/min), rectal temperatures (Temp, °F), and respiratory
rates (RR, breaths/min) over time (hours) for horses administered either an intravenous infusion
of saline solution (SALINE), LPS (LPS), doxycycline followed by LPS (DOXY),
oxytetracycline followed by LPS (OXYTET), flunixin meglumine followed by LPS
(FLUNIXIN), or pentoxifylline followed by LPS (PTX). †Significant (p ≤ 0.05) difference
from baseline (T=0) value within treatment group. *Significant (p ≤ 0.05) difference from LPS
group.
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Time

HR

SALINE
Temp

RR

HR

LPS
Temp

RR

HR

DOXY
Temp

RR

T=0

41 ± 7

100.2 ± 0.9

15 ± 3

43 ± 3

99.7 ± 0.7

13 ± 4

39 ± 7

100.2 ± 0.4

15 ± 4

T=0.5

43 ± 9*

100.3 ± 1.0

25 ± 10†*

54 ± 7†

100.1 ± 0.6

15 ± 3

49 ± 5†

100.6 ± 0.4

18 ± 6

T=1.0

44 ± 2*

100.2 ± 0.8

21 ± 9†

54 ± 8†

100.7 ± 1.1

17 ± 3

58 ± 8†

101.0 ± 0.3

20 ± 3†

T=1.5

43 ± 3*

100.3 ± 0.5*

22 ± 4†

60 ± 6†

101.5 ± 1.3†

19 ± 5†

60 ± 9†

101.5 ± 0.8†

17 ± 3

T=2.0

40 ± 6*

100.1 ± 0.4*

26 ± 8†*

59 ± 4†

102.7 ± 1.2†

15 ± 3

51 ± 4†

101.9 ± 1.2†

17 ± 4

T=3.0

37 ± 4*

100.1 ± 0.5*

27 ± 12†*

47 ± 8

103.1 ± 1.4†

18 ± 7

46 ± 4†

102.5 ± 1.8†

16 ± 5

T=4.0

42 ± 7*

100.4 ± 0.3*

24 ± 5†

50 ± 3†

102.7 ± 1.3†

19 ± 8†

46 ± 2†

102.1 ± 1.2†

15 ± 2

T=6.0

42 ± 4*

100.2 ± 0.4*

24 ± 6†*

51 ± 10†

101.2 ± 0.6†

15 ± 3

50 ± 5†

101.0 ± 0.8

16 ± 7

T=8.0

41 ± 3

100.3 ± 0.4

22 ± 4†

48 ± 6

100.6 ± 0.4†

15 ± 5

46 ± 6†

100.2 ± 0.5

22 ± 10†*

T=12.0

41 ± 5

99.9 ± 0.4

21 ± 3†

47 ± 8

100.5 ± 0.6†

14 ± 2

43 ± 3

100.1 ± 0.6

18 ± 8

T=16.0

39 ± 7

100.1 ± 0.4

18 ± 7

44 ± 8

99.9 ± 0.7

14 ± 2

39 ± 3

99.5 ± 0.7

16 ± 5

T=24.0

38 ± 2

99.8 ± 0.3

21 ± 7†*

41 ± 3

99.3 ± 0.6

13 ± 2

45 ± 8

99.7 ± 0.6

15 ± 4

Time

HR

OXYTET
Temp

RR

HR

FLUNIXIN
Temp

RR

HR

PTX
Temp

RR

T=0

40 ± 3

99.2 ± 0.9

12 ± 2

34 ± 8*

99.8 ± 0.3

14 ± 6

40 ± 0

99.6 ± 1.1

20 ± 13

T=0.5

51 ± 12†

100.1 ± 0.8

20 ± 7†

42 ± 8†*

100.5 ± 0.4

14 ± 3

48 ± 7

100.0 ± 1.2

22 ± 12

T=1.0

67 ± 7†*

100.0 ± 0.7

19 ± 4†

49 ± 8†

100.5 ± 0.3

15 ± 4

56 ± 4†

100.5 ± 1.5

24 ± 12

T=1.5

57 ± 7†

101.0 ± 0.5†

16 ± 5

50 ± 7†

100.7 ± 0.4†

19 ± 4†

52 ± 11†

101.1 ± 1.7†

24 ± 10

T=2.0

49 ± 8†*

101.1 ± 0.8†*

13 ± 4

48 ± 7†*

100.8 ± 0.4†*

14 ± 2

58 ± 8†

101.4 ± 1.6†

18 ± 4

T=3.0

42 ± 2

101.6 ± 0.7†*

14 ± 2

40 ± 9

101.3 ± 1.0†*

17 ± 7

51 ± 8†

101.8 ± 1.9†

23 ± 7

T=4.0

40 ± 4*

100.9 ± 1.5†*

15 ± 4

38 ± 11*

100.8 ± 0.8†*

16 ± 4

47 ± 7

102.1 ± 1.0†

23 ± 8

T=6.0

45 ± 3

99.9 ± 0.9*

14 ± 5

50 ± 9†

100.6 ± 0.7†

22 ± 8†

46 ± 10

101.0 ± 0.5†

19 ± 6

T=8.0

42 ± 5

100.4 ± 0.9†

12 ± 3

47 ± 3†

100.4 ± 0.4

18 ± 6†

47 ± 7

100.1 ± 0.6

25 ± 11*

T=12.0

42 ± 2

100.8 ± 0.3†

14 ± 4

49 ± 5†

100.6 ± 0.4

15 ± 5

52 ± 9†

100.4 ± 1.1

23 ± 9

T=16.0

46 ± 10

100.0 ± 0.6

11 ± 2

43 ± 6†

99.8 ± 0.5

13 ± 5

47 ± 7

99.7 ± 1.4

17 ± 8

T=24.0

42 ± 4

98.7 ± 0.6

15 ± 3

49 ± 4

99.6 ± 0.4

14 ± 4

43 ± 6

99.4 ± 0.6

19 ± 2
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plasma samples of all horses. The active forms of MMP-2 (66 kD) and MMP-9 (83 kD) were
not detected.
Study 1 – Administration of LPS significantly decreased proMMP-2 and increased
proMMP-9 concentrations in the digital venous plasma over time compared with baseline values
(Figures 4.1 and 4.2). Both proMMP-2 and proMMP-9 concentrations remained unchanged
from baseline in digital venous plasma samples from horses receiving saline solution (Figures
4.1 and 4.2). ProMMP-2 concentrations were significantly increased for the LPS group at 16.0
and 24.0 hours compared with horses administered saline solution (Figure 4.1). ProMMP-9
concentrations were significantly increased for horses administered LPS at 0.5, 1.0, 1.5, 2.0, 4.0,
12.0, 16.0, and 24.0 hours compared with horses administered saline solution (Figure 4.2).
Study 2 – ProMMP-2 concentrations remained unchanged compared with baseline values
for the DOXY, OXYTET, FLUNIXIN, and PTX treatment groups; however, proMMP-9
concentrations increased over time compared with baseline values despite treatment with MMPI
in these groups (Figures 4.3 – 4.10). Doxycycline significantly decreased proMMP-2
concentrations in the digital venous plasma at 1.0, 1.5, 2.0, 3.0, 4.0, 16.0, and 24.0 hours and also
decreased proMMP-9 concentrations at 0.5, 1.5, 6.0, and 8.0 hours compared with horses
receiving only LPS (Figures 4.3 and 4.4). ProMMP-2 concentrations were significantly
decreased for the OXYTET group at 0.5, 1.0, 16.0, and 24.0 hours compared with the LPS group
(Figure 4.5). The OXYTET group also had significantly decreased proMMP-9 concentrations
compared with the LPS group at 0, 0.5, 1.0, 1.5, 2.0, 3.0, and 4.0 hours (Figure 4.6). Flunixin
meglumine significantly decreased proMMP-2 concentrations at 0.5, 1.0, 1.5, 2.0, 4.0, 16.0 and
24.0 hours and significantly decreased proMMP-9 concentrations at 0.5 and 1.5 hours compared
with horses administered LPS alone (Figures 4.7 and 4.8). Administration of pentoxifylline
significantly decreased proMMP-2 digital venous plasma concentrations at 0, 0.5, 1.0, 16.0 and
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Figure 4.1 – Mean (± SD) proMMP-2 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or saline solution (SALINE).
+Significant (p ≤ 0.05) difference from baseline (T = 0) values for LPS group. *Significant (p ≤
0.05) difference between treatment groups.
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Figure 4.2 – Mean (± SD) proMMP-9 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or saline solution (SALINE).
+Significant (p ≤ 0.05) difference from baseline (T = 0) value for LPS group. *Significant (p ≤
0.05) difference between treatment groups.
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Figure 4.3 – Mean (± SD) proMMP-2 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or doxycycline followed by an
IV infusion of LPS (DOXY). *Significant (p ≤ 0.05) difference between treatment groups.
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Figure 4.4 – Mean (± SD) proMMP-9 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or doxycycline followed by an
IV infusion of LPS (DOXY). +Significant (p ≤ 0.05) difference from baseline (T = 0) value for
DOXY group. *Significant (p ≤ 0.05) difference between treatment groups.
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Figure 4.5 – Mean (± SD) proMMP-2 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or oxytetracycline followed by
an IV infusion of LPS (OXYTET). *Significant (p ≤ 0.05) difference between treatment groups.
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Figure 4.6 – Mean (± SD) proMMP-9 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or oxytetracycline followed by
an IV infusion of LPS (OXYTET). +Significant (p ≤ 0.05) difference from baseline (T = 0)
value for OXYTET group. *Significant (p ≤ 0.05) difference between treatment groups.
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Figure 4.7 – Mean (± SD) proMMP-2 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or flunixin meglumine followed
by an IV infusion of LPS (FLUNIXIN). *Significant (p ≤ 0.05) difference between treatment
groups.
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Figure 4.8 – Mean (± SD) proMMP-9 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or flunixin meglumine followed
by an IV infusion of LPS (FLUNIXIN). +Significant (p ≤ 0.05) difference from baseline
(T = 0) value for FLUNIXIN group. *Significant (p ≤ 0.05) difference between treatment
groups.
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24.0 hours and significantly decreased proMMP-9 concentrations at 0, 0.5, 1.0, 1.5, 2.0, and 3.0
hours compared with horses receiving only LPS (Figures 4.9 and 4.10).
4.4 Discussion
Intravenous infusion of endotoxin significantly increased MMP-2 and MMP-9
concentrations in the digital circulation of healthy adult horses. Horses receiving LPS
developed clinical signs associated with endotoxemia similar to previous reports.130,131 The
administration of doxycycline, oxytetracycline, flunixin meglumine, or pentoxifylline prior to
LPS administration resulted in significant decreases in MMP-2 and MMP-9 digital venous
plasma concentrations of varying degrees.
Early in the pathogenesis of experimentally-induced laminitis, a systemic inflammatory
response occurs that is localized to the digit including increased pro-inflammatory cytokine
induction, neutrophil infiltration, and MMP synthesis and release.178,195-197,200 Both MMP-2 and
MMP-9 activities are increased in digital laminar tissue of horses with clinical and
experimentally induced laminitis.82,84,85 Also, increases in MMP-9 concentrations have been
found in the systemic circulation of experimental CHO laminitis.206 Thus, it would seem likely
that synthetic inhibitors of MMPs may be useful in the treatment of this disease. The validation
of endotoxemia as a model of MMP induction in the digital circulation of the horse enabled
further study of MMPIs as potential treatments for laminitis without requiring the euthanasia of
numerous horses.
The non-proteolytic latent form of both MMP-2 and MMP-9 were identified in plasma
samples, but not the active forms. This is similar to results from experimental infusion of
endotoxin in humans and in other animals.134,136 Reportedly, in healthy tissue most of the
potential MMP activity is present in the latent form.82 ProMMPs can undergo allosteric
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Figure 4.9 – Mean (± SD) proMMP-2 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or pentoxifylline followed by an
IV infusion of LPS (PTX). *Significant (p ≤ 0.05) difference between treatment groups.
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Figure 4.10 – Mean (± SD) proMMP-9 band intensities (arbitrary units, A.U.) in the digital
venous plasma of horses receiving an IV infusion of LPS (LPS) or pentoxifylline followed by an
IV infusion of LPS (PTX). +Significant (p ≤ 0.05) difference from baseline (T = 0) value for
PTX group. *Significant (p ≤ 0.05) difference between treatment groups.
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activation without proteolysis of their active domain if they are in contact with the appropriate
substrate.31 Therefore, the zymogen forms may be up-regulated and released into the plasma, but
may be either awaiting activation by other proteases or seeking the appropriate substrate. In
addition, the active MMPs may have already become bound to substrate in tissues and be
unavailable for measurement in the plasma.
It is not surprising that endotoxin administration had only minor effects on MMP-2
activity compared with its effects on MMP-9 activity. Endotoxemia incites a severe
inflammatory response that initiates numerous mediator cascades, many of which are MMP
activators and substrates.15,16,22,125 Although MMP-9 can be constitutively expressed to some
extent, it is mostly induced in response to inflammatory mediators and released by neutrophils.7
Therefore, MMP-9 seems the mostly likely of the two gelatinases to be upregulated by endotoxin
exposure. Other studies have also shown that endotoxin induces predominantly MMP-9.230 The
constitutive nature of MMP-2 and the lack of response seen here upon exposure to LPS, lend
further evidence to the suggestion that MMP-2 is mostly involved in homeostasis and may
possibly even play a protective role. While the increases in proMMP-2 at 16.0 and 24.0 hours in
the LPS group were significant compared with all other groups, they were not significantly
increased compared to the LPS baseline value and seem to be merely fluctuations.
All of the MMPIs evaluated in this study were found to inhibit MMPs in the horse.
Flunixin meglumine appeared to have the greatest inhibitory effect on MMP-2 plasma
concentrations followed by doxycycline, pentoxifylline, and oxytetracycline. In contrast,
pentoxifylline was the most potent MMP-9 inhibitor, with oxytetracycline having only slightly
lesser inhibitory effects. Both doxycycline and flunixin meglumine had very little inhibitory
effects on MMP-9 in the horse.
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The NSAID flunixin meglumine, a non-selective COX inhibitor, had inhibitory effects on
both MMP-2 and MMP-9 in the horse in vivo. These findings differ slightly from other in vitro
results which indicated that neither flunixin meglumine nor phenylbutazone, another NSAID,
inhibited equine MMP-2 or MMP-9 obtained from equine cell culture.76 The effects of NSAIDs
on MMP inhibition have been extensively studied. Cyclooxygenase-2 increases activation of
MMPs, and NSAIDs, or COX inhibitors, decrease MMP-2 and MMP-9 expression.114-117 Other
research suggests that NSAIDs up-regulate mRNA expression of RECK, a membrane anchored
endogenous MMPI.118 Increased expression of RECK leads to decreases in MMP-2 activity and
suppression of MMP-9 release.231 Although RECK is inversely related to MMP-2 activation, it
is not related to MMP-9 activation. However, tumors with high RECK expression have a trend
toward decreased MMP-9 expression.39 Therefore, flunixin meglumine’s potent inhibitory
effects on MMP-2 as opposed to its weak effects on MMP-9 may be attributed to increased
expression of RECK and its apparent affinity for MMP-2 inhibition.
The results of this study suggest that pentoxifylline is a potent MMP-9 and modest
MMP-2 inhibitor in the horse. Phosphodiesterase inhibitors regulate MMP expression by
increasing intracellular cAMP concentrations that disrupt phosphorylation pathways and prevent
gene transcription.113,119 Pentoxifylline is a methyl xanthine derivative and phosphodiesterase
inhibitor commonly used for its rheological effects on peripheral vascular disease in people.120
Pentoxifylline has also been shown to decrease neutrophil infiltration and activation in the lung
and liver of rats administered endotoxin.119,232 Neutrophils are the predominant source of
MMP-9; therefore, the neutrophil inhibiting effects of pentoxifylline may account for a portion
of the decrease in MMP-9 activity demonstrated here.
Horses administered pentoxifylline had significantly lower baseline MMP-2 and MMP-9
concentrations compared with horses administered endotoxin alone. Likewise, oxytetracycline
86

had significantly lower baseline MMP-9 concentrations. Various cells constitutively produce
MMP-2 and, to a small extent MMP-9.7 The MMPI treatments were administered 12 hours prior
to endotoxin infusion; therefore, it is logical that baseline MMP concentrations could be
decreased because of inhibition already present at the time of LPS infusion. Inhibition of basal
MMP concentrations suggests that pentoxifylline and oxytetracycline are more potent MMPI in
the horse than doxycycline and flunixin meglumine. Furthermore, MMP-9 is usually induced by
inflammatory mediators and released from neutrophils, as previously stated. The above
mentioned neutrophil inhibitory effects of pentoxifylline may also account for the decreases in
baseline plasma MMP-9 concentrations.
Although doxycycline is a potent MMP-9 inhibitor in other species and the only drug
approved for MMP inhibition in humans, it surprisingly had only minimal effects on endotoxininduced MMP-9 activity in this study. However, it was a potent MMP-2 inhibitor, along with
flunixin meglumine. This is unusual because other reports indicate that doxycycline
predominantly inhibits MMP-9 and in some cases has no inhibitory effect on MMP-2.101,230
Matrix metalloproteinase inhibition by tetracyclines is believed to occur by chelation of Zn2+
ions at the binding site in the catalytic domain of MMPs.112 Other studies indicate that they
regulate MMP gene expression by affecting mRNA stability.233 Doxycycline may also decrease
MMP-9 secretion through up-regulation of its endogenous inhibitor, TIMP-1.101
Doxycycline has been reported to cause cardiovascular collapse and death when
administered IV to horses; therefore, in this study, the drug was administered via nasogastric
intubation (NGT). Endotoxemia leads to decreased gastric and intestinal motility through the
activation of COX and subsequent production of PGE2.149,160 It is possible that NGT
administration of doxycycline in this study may have led to decreased absorption and decreased
MMP inhibition. To determine if decreased absorption occurred, plasma doxycycline
87

concentrations were determined. Plasma doxycycline concentrations peaked 0.5 hour after NGT
administration with a mean of 0.97 ± 0.34 µg/ml. This is consistent with reported maximum
steady-state doxycycline serum concentrations of 0.94 µg/ml achieved after oral administration
in horses at 10 mg/kg every 12 hours.234 Therefore, the low degree of MMP inhibition obtained
in this study does not appear to be due to decreased intestinal absorption. However, the
maximum steady-state serum concentrations reported above correspond with the MIC for certain
bacteria. Perhaps serum concentrations of doxycycline required for adequate MMP inhibition
are much greater than the MIC; therefore, the dose used in this in vivo study would not have been
sufficient for maximal MMP inhibition. Furthermore, this would also explain why doxycycline
had greater MMP inhibitory effects in the confined explant culture environment. The equivalent
in vivo dose required would be approximately 5X the maximum safe dosage; therefore, it would
not be an advisable dose to investigate in vivo.
Oxytetracycline had a much greater effect on equine MMP inhibition than doxycycline.
It was both a potent MMP-9 inhibitor and a modest MMP-2 inhibitor. The effects of
oxytetracycline on MMP-2 and MMP-9 inhibition have not been studied previously. It appears
that oxytetracycline has greater inhibitory effects on MMP-9 than MMP-2, as is seen with other
tetracyclines.101,230
Tetracyclines are excreted through the biliary duct into the intestine; therefore, there is a
risk for the development of diarrhea following administration at higher doses due to intestinal
microbial alterations.234 Several studies have demonstrated the safety of oral administration of
doxycycline at both 10 mg/kg every 12 hours and 20 mg/kg every 24 hours.108-110
Oxytetracycline has been used safely in horses at dosages ranging from 5 – 40 mg/kg IV.235 In
this study, none of the horses administered doxycycline at a dose of 10 mg/kg or oxytetracycline
at a dose of 20 mg/kg IV every 12 hours developed diarrhea.
88

Establishing non-terminal models for the study of disease is important in any field of
research, but especially in equine research. This study has demonstrated that experimentallyinduced endotoxemia can be used as a non-terminal, in vivo model for the induction and
investigation of MMPs in the horse. Furthermore, pentoxifylline, oxytetracycline, flunixin
meglumine, and doxycycline were all found capable of inhibiting equine MMPs. Flunixin
meglumine and doxycycline appeared to be weak MMP-9 and potent MMP-2 inhibitors.
However, pentoxifylline and oxytetracycline were both potent MMP-9 and moderate MMP-2
inhibitors in the horse. Past studies suggest that MMP-9 may play a more important role in
laminitis; therefore, pentoxifylline and oxytetracycline warrant further study for use as
treatments/preventatives for equine laminitis.
4.5 Product Information
a

Lipopolysaccharide from E. coli O55:B5 L2880, Sigma-Aldrich, St. Louis, MO

b

c

Doxycycline hyclate, Ranbaxy Pharmaceuticals, Princeton, NJ

Liquamicin LA-200, Pfizer Animal Health, St. Louis, MO

d

Banamine, Schering-Plough Animal Health, Union, NJ

e

Pentoxifylline, HDM Pharmacy, Lexington, KY

f

10% Gelatin Ready Gel 161-1167, Bio-Rad Laboratories, Hercules, CA

g

MMP-2 Proenzyme PF037 and Active PF023, Calbiochem, La Jolla, CA

h

MMP-9 Proenzyme PF038 and Human Recombinant PF024, Calbiochem, La Jolla, CA

i

Image J, U.S. National Institutes of Health, Bethesda, MD

j

SAS v 9.0, SAS Institute, Cary, NC
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CHAPTER 5. SUMMARY
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Acute laminitis is a debilitating disease affecting the equine foot, of which the
pathogenesis is incompletely understood despite years of research. Recent studies have
suggested that MMP-2 and MMP-9 may be responsible for the laminar destruction seen with this
disease. Laminitis often occurs secondary to many diseases such as endotoxemia, which has also
been associated with increases in MMP activity. In human medicine, MMPIs have been
investigated as potential treatments for various MMP-associated diseases; therefore, MMPIs may
be helpful in the treatment/prevention of equine laminitis. This doctoral research had three main
goals: 1) to collect MMP-9 from equine neutrophils and to validate a human MMP activity assay
for use with equine samples as a more complete evaluation of MMP activity compared with
zymography; 2) to validate experimental endotoxemia as a non-terminal model for MMP
induction in the horse; and 3) to use the MMP induction model to evaluate the effectiveness of
various MMPIs in the horse.
Equine MMP-9 was successfully harvested from neutrophils and characterized. The
Biotrak MMP-9 Activity Assay had low sensitivity to equine MMP-9; therefore, it could not be
used for quantification of MMPs in these studies. In vitro, doxycycline and oxytetracycline
significantly increased digital laminar explant structural integrity. Furthermore, doxycycline,
oxytetracycline, and flunixin meglumine all significantly decreased MMP-2 and MMP-9
concentrations in the medium of digital laminar explants incubated with endotoxin. Laminar
structural integrity and medium MMP-2 concentration were inversely correlated. Intravenous
infusion of endotoxin to healthy adult horses significantly increased digital venous plasma
MMP-2 and MMP-9 activities compared with IV infusion of a saline solution. Pre-treatment with
oral doxycycline or IV flunixin meglumine significantly decreased digital plasma MMP-2
concentrations, but merely blunted MMP-9 concentrations in healthy adult horses. However,
pre-treatment with IV pentoxifylline and IV oxytetracycline profoundly inhibited the effects of
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endotoxin on plasma MMP-9 concentrations and modestly inhibited plasma MMP-2
concentrations in healthy adult horses.
An established model of experimentally-induced endotoxemia was successfully validated
for use as a non-terminal in vivo method of MMP induction in healthy adult horses. This model
was used to determine that doxycycline and flunixin meglumine are potent MMP-2 inhibitors in
the horse, whereas pentoxifylline and oxytetracycline are far more potent MMP-9 inhibitors.
The in vitro results agree that oxytetracycline was a superior MMP-9 inhibitor; however, it was
also significantly inhibited MMP-2 in the laminar explants. Flunixin meglumine also appeared
to be a significant MMP-9 inhibitor in vitro, but not in vivo. These results demonstrate the
variations that can be seen when tissues are isolated in the culture environment. Unfortunately,
pentoxifylline was not evaluated in vitro. It would be interesting to determine if pentoxifylline’s
MMP inhibitory actions would be the same in explant culture as in the digital circulation of the
horse.
MMPIs may have significant roles in the future of veterinary medicine, especially in
regard to equine laminitis. The validation of a non-terminal model for the study of MMPIs in the
horse has great significance. It will not only allow pre-screening of potential drugs for use in
experimental CHO laminitis studies, but can also be used in the study of other equine diseases
associated with increases in MMPs. The data presented here suggest that the MMP inhibitory
effects of pentoxifylline and oxytetracycline should be evaluated in an experimental equine
laminitis model as potential treatments/preventatives.
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